

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Prevalence and Practices of Unsafe Medical Injection and Infusion among People Living with HIV (PLWH) in Cambodia

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-065026
Article Type:	Original research
Date Submitted by the Author:	25-May-2022
Complete List of Authors:	Seang, Kennarey; University of Health Sciences Khim, Keovathanak; The University of Melbourne, Nossal Institute for Global Health Vyas, Kartavya; Emory University, Epidemiology Khuon, Dyna; University of Health Sciences Faculty of Medicine Saphonn, Vonthanak; University of Health Sciences Gorbach, Pamina; University of California Los Angeles, Department of Epidemiology
Keywords:	Epidemiology < INFECTIOUS DISEASES, HIV & AIDS < INFECTIOUS DISEASES, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Prevalence and Practices of Unsafe Medical Injection and Infusion among People Living with HIV**
5 **(PLWH) in Cambodia**
6
7
8
9
10
11

12 Kennarey Seang^{1*}, Keovathanak Khim², Kartavya Vyas³, Dyna Khuon¹, Vonthanak Saphonn^{1§}
13 and Pamina Gorbach^{4§}
14
15

16
17
18
19 ¹ University of Health Sciences, Phnom Penh, Cambodia

20 ² National Institute of Public Health – School of Public Health, Phnom Penh, Cambodia

21 ³ Department of Epidemiology, Emory University, Atlanta, USA

22 ⁴ Department of Epidemiology, University of California Los Angeles, Los Angeles, USA
23
24
25
26
27

28 * Corresponding author: Kennarey Seang
29

30 73 Monivong Boulevard

31 Phnom Penh, 12201, Cambodia

32 Email: seang.kennarey@gmail.com
33
34
35
36
37
38
39
40
41

42 §Joint last authors.
43
44
45
46

47 E-mail addresses of authors:
48

49 KS: seang.kennarey@uhs.edu.kh | seang.kennarey@gmail.com

50
51 KK: kkvathanak@gmail.com

52
53 KV: kartavya.vyas@gmail.com
54
55
56
57
58
59
60

1
2
3
4 DK: khuondyna@yahoo.com
5

6 VS: vonthanak@uhs.edu.kh
7

8 PMG: pgorbach@ucla.edu
9
10
11
12
13
14
15

16 *Keywords:* injection, PLWH, unsafe injection, HIV, injection prevalence, injection practices
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: In late 2014, an outbreak of HIV due to having received medical injections from unlicensed medical providers in rural Cambodia highlighted the need to assess medical injection practices among those who are at risk of acquiring and/or transmitting HIV. This study examined medical injection/infusion behaviours among people living with HIV (PLWH) and those who were HIV-negative in Cambodia so that these behaviours can be properly addressed if they were to be quite prevalent, especially among the patients.

Design: A cross-sectional survey was conducted in order to examine injection behaviours and estimate the injection prevalence and injection rates by HIV status. Unsafe injections/infusions were those received from village providers who do not work at a health centre or hospital, or traditional providers at participant's (self-injection included) or provider's home. Logistic regression was performed to examine the relationship between unsafe injection/infusion and HIV, adjusting for sex, age, education, occupation, residence location, and other risk factors.

Setting: The survey was conducted in 10 HIV testing and treatment hospitals/clinics across selected provinces in Cambodia, from February to March, 2017.

1
2
3
4 **Participants:** A total number of 500 volunteers participated in the survey, 250 patients and 250
5
6
7 HIV-negative individuals.
8
9

10 **Primary and secondary outcome measures:** Measures of injection prevalence and other risk
11
12
13
14 behaviour distribution were based on self-reports.
15

16
17 **Results:** Despite lower annual injection/infusion rates from all types of providers (three
18
19
20 injections per person in PLWH vs four injections per person in HIV-negative), PLWH were
21
22
23
24 more likely to have had an unsafe last injection/infusion, aOR=1.84 (95% CI: 0.71-4.80).
25

26
27 **Conclusions:** The inclination for medical injections and infusions (unsafe at times) among
28
29
30 PLWH in Cambodia was a common practice and could possibly represent yet another
31
32
33
34 opportunity for parenteral transmission outbreak.
35

36 37 38 39 40 **Strengths and limitations of the study** 41

- 42
43
44 • Our study's assessment of self-recall injection behaviours over 12 months could better
45
46
47 reflect injection use and avoid capturing only certain fluctuations, as medical injections
48
49
50 or infusions are relatively uncommon events. This, complemented with the questions on
51
52
53
54
55
56
57
58
59
60

1
2
3 the last injection received over the same period to capture a more recent behaviour helped
4
5
6
7 complete the risk profile assessment.
8
9

- 10 • Our study captured 92% of PLWH had been diagnosed more than two years prior,
11
12 therefore, prevalent cases, they were most likely got infected during the early 90's
13
14 through unsafe sexual behaviours and not through unsafe injection practices, making
15
16 reverse causation a weak case in our study.
17
18
- 19 • The study looked at not only the providers of the last injection or infusion (received
20
21 within the past year), but also facility types at which these medical injections took place.
22
23 These helped a more accurate assessment of formal vs. informal providers, especially in
24
25 the Cambodian setting, where the majority of peddlers or village providers (not working
26
27 in the hospitals) were likely unlicensed providers without proper medical training.
28
29
- 30 • The majority of these behaviours were based on self-reports, from the participants or
31
32 patients, unfortunately; the assessment from the provider side could help to completely
33
34 understand the injection practices and form a better-informed recommendation.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 Introduction

1
2
3
4
5 The World Health Organization (WHO) considered over or unnecessary use of injections
6
7
8 as unsafe injection practices, alongside the use of unsafe methods for injection, such as reusing
9
10
11 syringe and needles [1, 2]. In some parts of the world, particularly in low- and middle-income
12
13
14 countries (LMICs), this common medical procedure is being performed daily using unsafe (yet
15
16
17 avoidable) injection practices which put both patients and communities at risk of bloodborne
18
19
20 pathogen transmission [1-5]. In late 2014, a rural community in Cambodia had a large outbreak
21
22
23 of human immunodeficiency virus (HIV) when an unlicensed medical practitioner infected 242
24
25
26 villagers aged between 2 and 89 years through his use of contaminated injection equipment [6,
27
28
29
30
31
32 7]. In early 2018, another two HIV outbreaks linked with unsafe injection practices occurred in
33
34
35 India and Pakistan [3]. These incidents demonstrated the ongoing risk of outbreaks related to
36
37
38 medical injection around the world, specifically in the LMICs.
39
40
41

42 In Cambodia, private health care providers are commonly sought for care. Although
43
44
45 many of them are public healthcare workers who practice privately during off-working hours,
46
47
48 there are also providers, mainly in rural areas, who are unlicensed private practitioners from
49
50
51
52 whom the community seeks medical care including (but not limited) to injections and infusions.
53
54
55
56
57
58
59
60

1
2
3
4 This is not uncommon in some parts of LMICs in which a person without proper training or
5
6
7 education in administering certain medical procedures provides medical injections [4].
8
9

10 The last Cambodia Demographic and Health Survey (CDHS 2014) assessed injection
11
12
13 practices as part of their behavioural survey among the general population. According to their
14
15
16
17 report, the prevalence of medical injection (having had any medical injections from health
18
19
20 worker in the past 12 months) among the Cambodian population aged 15-49 was approximately
21
22
23 35% (or 37% and 27% among women and men, respectively) [8]. Previous studies on injection
24
25
26 use and safety practices (including the DHS survey) in Cambodia usually focused on the general
27
28
29 population [9]. These behavioural risk factors have not been studied among people living with
30
31
32
33 HIV (PLWH), despite the fact that the risk of getting or transmitting bloodborne pathogens
34
35
36 among this population are heavily shaped by these behaviours. We suspected that PLWH might
37
38
39 be seeking medical injections at a higher rate than the general population for several reasons.
40
41
42
43 First, being in regular care gives PLWH more opportunities to get diagnosed with various
44
45
46
47 medical conditions and receive treatments. Second, PLWH often suffer from significantly more
48
49
50 co-morbidities, such as age-related non-communicable diseases and mental or neurological
51
52
53
54
55
56
57
58
59
60

1
2
3 disorders, than the general population [10, 11]. For these reasons, PLWH might be in greater
4
5
6
7 need of medical treatments, such as injections, than the general population.
8
9

10 Ever since the 2014 HIV outbreak in Roka village, there have been no other studies
11
12
13 assessing injection behaviours among PLWH elsewhere; and the CDHS reported only medical
14
15
16
17 injections given by health care workers. Without assessment of injection and infusion practices
18
19
20 in people who are at risk of transmitting and acquiring HIV, it is challenging for public health
21
22
23 professionals to advise or prepare public health measures which are both appropriate and
24
25
26
27 efficient to address unsafe injection practices. Our study aims to primarily characterize injection
28
29
30 practices among PLWH and those who were HIV-negative and determine whether the first group
31
32
33 were at higher risk of seeking medical injections from informal providers.
34
35
36

37 Although when considering unsafe medical injections, people usually refer to used
38
39
40 syringes and needles, we considered (in this paper) injections provided by unlicensed (medical)
41
42
43 practitioners unsafe as well. Understanding these injection seeking behaviours among this
44
45
46
47 population is helpful for planning necessary public health measures as well as improving access
48
49
50 to formal healthcare facilities.
51
52

53 **Methods**

54
55
56
57
58
59
60

Study setting

Cambodians seeking HIV care or HIV testing were recruited for this study from HIV voluntary testing sites in Cambodia and HIV/AIDS treatment and care clinics (called Opportunistic Infections/Antiretroviral Therapy (OI/ART) sites). These sites are under the supervision of the National Centre for HIV/AIDS, Dermatology and STD (NCHADS) and there are 52 of them across Cambodia. These sites transmit their patients' follow-up visit information (for people in care) or new information (for newly-tested positive patients) to NCHADS database on a regular basis.

Inclusion and exclusion criteria

Participants were eligible if they were: at least 18 years of age on the day of interview, people who are living with HIV (PLWH), that is those who have known HIV+ status, or HIV- status (after having had their HIV test result) and are willing and able to provide written informed consent to take part in the study on the data collection day. Excluded were individuals who are not willing or able to complete the questionnaire or present any other condition that, in the opinion of the research or local healthcare staff, would preclude informed consent.

Study design, sampling and recruitment

1
2
3
4 We conducted a cross-sectional study comparing PLWH ($n=250$) who came to receive
5
6 their HIV treatment care and those who came to have HIV testing and had a negative result
7
8
9
10 ($n=250$) at selected HIV clinics in five provinces and the capital city of Cambodia, from early
11
12 February to the end of March 2017. The sample size of 250 per group was calculated to provide
13
14 90% power to test the hypothesis using a two-sample comparison of proportions where the first
15
16 proportion was set at 20% of injection use (HIV-negative participants) and the second proportion
17
18 was set at 35% (HIV-positive participants). A two-stage sampling approach was employed for
19
20 participant selection. First, we selected 10 sites and out of the 52 sites with joint testing/OI/ART
21
22 services (meaning those with both testing and OI/ART services) using probability-proportional-
23
24 to-size (PPS) method. Next, we consecutively sampled PLWH who came for their regular clinic
25
26 visit or pharmacy refill at the selected sites. In a similar manner, HIV-negative individuals who
27
28 came to selected sites for HIV testing who got a negative result were approached for recruitment.
29
30
31 We compared these two groups of participants for their similar HIV behavioural risk profile. It
32
33
34 should be noted that those who come to the HIV/AIDS clinics for (voluntary) HIV testing, more
35
36
37 often than not, those who are part of the population who are at risk of getting HIV (Men who
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 have Sex with Men “MSM”, Injection Drug Users “IDU” and Entertainment Workers “EW”
4
5
6
7 and are regularly tested for HIV/AIDS.
8
9

10 **Medical history and behavioural assessment**

11
12
13 HIV-specific factors (HIV status and date of HIV test, WHO disease stage, etc.) were
14
15
16 obtained from linkage with the NCHADS database. Behavioural data were collected using a
17
18
19 Computer-Assisted Person Interview (CAPI) technique, administered via tablet and questions
20
21
22 were guided by literature. Participants were asked to report on socio-demographic factors, such
23
24
25 as date of birth, sex, education, marital status, occupation, general location of residence (village,
26
27
28 community, district and province) and a wide range of behavioural factors including history of
29
30
31 illicit injection drug use (IDU), alcohol and tobacco use, informal medical injection/infusion use,
32
33
34 such as frequency, and type of provider.
35
36
37
38
39

40 **Definition and classification**

41
42
43 The outcome of interest, unsafe medical injection (or infusion), was defined as having
44
45
46 received last injection or infusion (within the past year) at participant’s or provider’s home from
47
48
49 village providers who do not work at health centre or hospital, traditional providers, or by self-
50
51
52 injection. In Cambodia and especially in rural areas, these health workers might also provide
53
54
55
56
57
58
59
60

1
2
3 some basic medical services (including injections and infusions) at their patient's home or in
4
5
6
7 private hospitals/clinics. Therefore, regardless of where the patients receive the injections, as
8
9
10 long as they were provided by the providers who work at hospital or health centre, we considered
11
12
13 these injections safe. Both intravenous and intramuscular injections were included in the
14
15
16
17 questionnaire and reporting.
18
19

20 The prevalence of medical injections counted those who reported at least one injection or
21
22
23 infusion (over the past year), but excluded vaccinations, non-medical injections and rare medical
24
25
26
27 injections such as transfusion.
28
29

30 **Statistical analysis**

31
32
33 We computed percentages and means of the key characteristics by HIV status (Table 1).
34
35
36
37 We first calculated the prevalence of having had at least one medical injection from health
38
39
40 workers and from all provider types over the past year among the participants (by their HIV
41
42
43 status). Chi-square and Exact tests were used for categorical variables and t-test for continuous
44
45
46
47 variables. Next, the average number of past year's medical injections from each type of providers
48
49
50 by HIV status was also computed and we reported the *P* derived from Poisson regression.
51
52
53
54 Finally, to examine the relationship between unsafe medical injection practices and HIV status,
55
56
57
58
59
60

1
2
3 we performed a logistic regression, adjusting for sex, age, education, occupation, residence
4
5
6 location, injection preference and other risk factors. All analyses were done in STATA 14.
7
8
9

10 **Patient and public involvement**

11
12
13 The patients, care givers and those who sought HIV testing but were negative participated
14
15
16 in the data collection of the study. Preliminary results of the study had been presented at the
17
18
19 University of Health Sciences at the 2018 Scientific Days among invited care givers, students
20
21
22 and other invited guests and researchers.
23
24
25

26 **Results**

27
28
29 We presented key characteristics by HIV status in Table 1. [Insert Table 1 here] The
30
31
32 socio-demographic factors are vastly different between the two groups in terms of age, marital
33
34
35 status, educational background and occupation. PLWH appeared to be much older – mean age
36
37
38 was 43 years (SD 9), of a lower educational background and married, while the majority of HIV-
39
40
41 negative participants were younger – mean age was 31 years (SD 11), more educated and single.
42
43
44 However, both groups were comparable in terms of their sex, income and residence location
45
46
47
48
49
50
51 distribution. Female participants accounted for about 66% ($n=164$) of PLWH and 71% ($n=177$)
52
53
54
55
56
57
58
59
60

of those uninfected. The majority of participants from both groups were from the provinces, 91% ($n=227$) among PLWH and 93% ($n=231$) among the uninfected.

Table 1. Key characteristics of study participants by HIV status, Informal Medical Injection

Study ($n=500$), Cambodia, 2017

Socio-demographics	HIV+		HIV-		<i>P</i>
	<i>(n=250)</i>		<i>(n=250)</i>		
	<i>n</i>	<i>%</i>	<i>n</i>	<i>%</i>	
Gender					
Female	164	65.6	177	70.8	.21
Male	86	34.4	73	29.2	
Age ^a (Mean, SD)	(43.1, 9.0)		(30.6, 10.7)		<.001
Marital status					
Single	15	6.0	87	34.8	<.001
Married	140	56.0	141	56.4	
Divorced	41	16.4	15	6.0	
Widowed	54	21.6	7	2.8	
Education					
Secondary or higher	104	41.6	163	65.2	<.001
Primary or less	146	58.4	87	34.8	
Occupation ^a					
Unemployed	81	32.7	126	50.8	<.001
Self-employed/farmers	95	38.3	70	28.2	
Employed	72	29.0	52	21.0	
Household annual income ^{a,b} (USD)					
> 3,000	40	22.9	44	22.8	.48
1,800-3,000	45	25.7	42	21.8	
1,001-1,800	39	22.3	56	29.0	
≤ 1,000	51	29.1	51	26.4	
Current address ^a					
Province	227	90.8	231	92.8	.42

Phnom Penh	23	9.2	18	7.2	
Other behavioral risk factors ^c					
Smoke monthly or more often	30	12.0	13	5.2	<.01
Feeling drunk monthly or more often	45	18.0	63	25.2	.05
Contact with syringe and needle at workplace	8	3.2	36	15.5	<.01
Had at least one hospitalization	42	23.5	87	49.2	<.001

SD, Standard Deviation.

^aMissing (HIV+, HIV-, respectively): age ($n=5$, $n=5$); occupation ($n=2$, $n=2$); other behavioral risk factors ($n=75$, $n=57$); current address ($n=0$, $n=1$).

^bThe categories for household income used quartiles to assure sufficient numbers in each category.

^cSelf-report over the past year.

Injection/infusion use

Injection and infusion practices are described in Table 2. [Insert Table 2 here] We found that the average annual number of injection/infusion from health workers was about three and four injections per person among PLWH and those who were HIV-negative, respectively ($P<.001$). The prevalence of any medical injection/infusion provided by health workers over the past year was higher among HIV-uninfected participants, 72% ($n=153$), compared to 40% ($n=61$) among those who were HIV-positive ($P<.001$). However, the prevalence of past year's injection/infusion from all providers between the two groups were comparable, 47% ($n=66$) among PLWH and 54% ($n=110$) among those uninfected ($P=.24$).

Table 2. Injection practices of study participants by HIV status, Informal Medical Injection

Study ($n=500$), Cambodia, 2017

Injection and infusion practices	HIV+ ($n=250$)		HIV- ($n=250$)		<i>P</i>
	<i>n</i>	%	<i>n</i>	%	
Injection and infusion use					
Last injection/infusion within past year					
Given by relative/acquainted provider	51	23.0	50	22.8	.97
Recommended by provider	54	85.7	131	90.3	.33
Given at public hospital	35	44.9	97	54.5	.16
Given at private hospital/clinic	29	53.7	58	46.0	.35
Given at their own home	16	31.4	24	21.2	.16
Number of injections/infusions within past year					
More than last year	107	67.7	144	66.4	.78
From health workers (mean, SD)		(3.2, 7.5)		(4.3, 7.1)	<.001
From all providers (mean, SD)		(3.5, 7.1)		(4.4, 7.8)	<.001
At least one - health worker	61	40.4	153	72.5	<.001
At least one - all providers	66	47.5	110	53.9	.24
Prefer injection to other treatments ^a	124	49.6	145	58.0	.06
Injection and infusion safety					
Last injection within past year					
Unsafe ^b last injection	11	15.5	11	7.3	.06
Provider did not use new, unopened syringe/needle	0	0.0	6	3.8	.19
Last injection within past year					
Unsafe ^b last infusion	10	13.5	13	10.5	.52
Provider did not use new, unopened syringe/needle	0	0.0	3	2.5	.55

SD, Standard Deviation.

^aThe questions on this preference pertain to several tracer conditions (in which case medical injections are clearly unnecessary).

^bAdministered at participant's or provider's home by village providers who do not work at health centre or hospital, traditional providers, or self-injection.

When asked about the last injection/infusion they received within the past year, PLWH were more likely to report having received their last one(s) at a private hospital/clinic, 54 % ($n=29$), or at their own home, 31% ($n=16$), compared to a 46% ($n=58$) and 21% ($n=24$), respectively, reported by their HIV-negative counterparts. HIV-negative participants were more likely to have received their last injection/infusion at a public hospital, 54% ($n=97$), as opposed to 45% ($n=35$) of PLWH ($P=.16$). Figure 1 broke down last injection and infusion by facility types in more details. [Insert Figure 1 here]

Regardless of HIV status, public and private sector accounted for the majority of medical injection and infusion received. Although none of our PLWH reported having received their last injection or infusion at traditional healer's home, a substantial amount of them reported having received their last injection (15% ($n=9$)) and infusion (22% ($n=14$)) at their own home.

A large number of participants from both groups, 50% ($n=124$) of PLWH and 58% ($n=145$) of those uninfected, reported that they preferred injection/infusion to other forms of treatment when sick ($P=.06$). Moreover, more than 60% of participants from both groups

1
2
3 indicated that they had actually received more injections the past year than previous year.
4
5

6
7 Similarly, over 80% of both PLWH and HIV-negative participants reported that their last
8

9
10 injection was in fact recommended by their care provider.
11
12

13 **Injection/infusion safety practices**

14

15
16 About 4% ($n=6$) of HIV-negative participants reported that the provider for their last
17
18 injection did not use a new, unopened package of syringe and needles while none of PLWH
19
20 reported this practice ($P=.06$). Although the average annual injection/infusion rates from all
21
22 provider types (including health workers) were slightly lower among PLWH (three injections per
23
24 person) compared with those who were HIV-negative (four injections per person) ($P<.001$), we
25
26 observed a slightly larger proportion of PLWH reported an unsafe last injection within the past
27
28 year, 15% ($n=11$) vs 7% ($n=11$) reported by those who were HIV-negative ($P=.06$). Likewise,
29
30 13% ($n=10$) of PLWH reported an unsafe last infusion within the past year, compared to 10%
31
32 ($n=13$) of HIV-uninfected participants ($P=.52$). Regardless of whether they live in the provinces
33
34 or the capital city “Phnom Penh” (Figure 2), the majority of participants from both groups
35
36 reported their provider recommended their last injection/infusion and more HIV- participants
37
38 than PLWH received their last injection/infusion from health workers. [Insert Figure 2 here] In
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 figure 3, overall, we saw similar patterns across the country, except provinces in the central and
4
5
6
7 north-eastern parts of Cambodia where injection/infusion use appeared the highest. [Insert Figure
8
9
10 3 here]
11
12

13 Association between unsafe medical injection/infusion and HIV

14
15
16
17 Table 3 presents the crude, adjusted OR and the 95% CI of the relationship between
18
19
20 unsafe last medical injection and HIV status. [Insert Table 3 here] Before adjustment, only sex,
21
22
23 occupation and presence of two or more risk behaviours were associated with having had unsafe
24
25
26 last injection or infusion (Table 3). HIV status appeared to be positively associated with unsafe
27
28
29 medical injection/infusion, cOR=1.45 (95% CI: 0.70-3.00). After adjusting for other covariates,
30
31
32
33
34 PLWH were almost twice more likely to have had an unsafe last injection or infusion than those
35
36
37 who were HIV-negative, aOR=1.84 (95% CI: 0.71-4.80).
38
39

40
41 Table 3. Association between getting unsafe medical injection and HIV status, Informal Medical
42
43
44 Injection Study ($n=500$), Cambodia, 2017
45
46

47 Outcome: unsafe injection/infusion	48 Crude OR	49 95 % CI	Adjusted OR ^a	95 % CI
50 HIV + (ref. HIV-)	1.45	0.70-3.00	1.84	0.71-4.80
51 Male (ref. female)	2.17	1.03-4.57	2.37	1.00-5.62
52 Age	1.00	0.97-1.03	0.98	0.94-1.02
53 Education (ref. secondary or higher)				

Primary or less	0.70	0.33-1.46	0.96	0.41-2.23
Occupation (ref. unemployed)				
Farmers and self-employed	0.91	0.41-2.01	0.83	0.36-1.91
Employed	0.48	0.17-1.36	0.59	0.20-1.72
Current address in Phnom Penh (ref. in provinces)	1.18	0.33-4.23	1.02	0.27-3.88
Prefer injection or infusion when sick (ref. no preference)	0.59	0.29-1.21	0.66	0.32-1.40
Had at least two risk behaviours ^b	0.67	0.19-2.33	0.47	0.13-1.75

CI, Confidence Interval.

Unsafe injection/infusion: last injection/infusion within the past year administered at participant's or provider's home by village providers who do not work at health centre or hospital, traditional providers, or self-injection.

^aAdjusted for gender, age, education, occupation, residence location, injection or infusion preference, and presence of two or more risk behaviours.

^bCombination of risk behaviours include: one or more hospitalization, contact with syringe and needle, smoking monthly or more often and feeling drunk monthly or more often in the past year.

Discussion

In our study, we found a high prevalence of medical injections (having had any medical injections in the past year from health workers) among the study participants in general (almost 60%), but PLWH were more likely to have had unsafe last injection or infusion (having received their last injection from informal providers), compared with those who were HIV-negative.

Regardless of the reasons for medical injections (with few exceptions), this practice is very common, and should be addressed, whether it is the patients' false beliefs that injectable drugs

1
2
3 work better than oral ones for certain medical conditions or the tendency to over-prescribe these
4
5
6
7 injectables.
8
9

10 According to the 2014 CDHS, there were great variations of injection prevalence
11
12
13 (administered by health workers) across the provinces ranging from 12% to 45% among women
14
15
16 and from 15% to 43% among men, and the average annual number of injections is between one
17
18
19 to two per person [8]. We found a much higher prevalence among our study sample, our results
20
21
22 were more in line with an article published in 2004 by Vong et al. that also looked at medical
23
24
25 injections in Cambodia found a 40% of medical injection prevalence and average number of
26
27
28 injection (over the past six months) of 5.9 per person [9]. It should be noted that both the 2004
29
30
31 study and the 2014 DHS examined the injection practices among the general population outside
32
33
34 of HIV setting (treatment or testing), and that it was unclear in the CDHS if infusions were also
35
36
37 counted for their injection reporting. Our study grouped infusions with injections when reporting
38
39
40 prevalence, similar to the 2004 study (Vong et al), but our study reported the injection
41
42
43 behaviours over the past year instead of over six months like Vong et al did. Several other factors
44
45
46 such as limited education, tendency of prescribers to recommend and participant's personal
47
48
49 preference of injection and the study population could be responsible for higher rates being
50
51
52
53
54
55
56
57
58
59
60

1
2
3 reported in our study compared with others. However, these seemed consistent with a recently
4
5
6
7 published paper which found high Hepatitis C prevalence among Cambodian population that is
8
9
10 likely due to medical injections [12]. Similarly, a review paper published in 2016 also reported a
11
12
13 12-month medical injection prevalence ranging from 30% to 68% across studies conducted in
14
15
16 south Asia [13].
17
18

19
20 The older mean age of our patients might also explain the high prevalence of medical
21
22
23 injections among them. The age distribution of PLWH in Cambodia is actually weighed down by
24
25
26 those who had been infected in the early 90's; and as the HIV incidence had been decreasing
27
28
29 since 2000, fewer people had become infected since then [14]. Because PLWH in the study were
30
31
32 on average older, they could be sicker and, therefore, sought more medical procedures including
33
34
35
36
37 injections.
38
39

40 The study should be interpreted with consideration to a number of limitations. First, our
41
42
43 assessment of the outcome was based on self-recall over a relatively long period (12 months)
44
45
46
47 which might cast some doubts over the accuracy of the answers given. However, to properly
48
49
50 reflect on injection use and avoid capturing only certain fluctuations, a longer period recall is
51
52
53 more reasonable. In addition, medical injections or infusions are generally uncommon events so
54
55
56
57
58
59
60

1
2
3
4 recalling them might not be too challenging. We also complemented this with the questions on
5
6
7 the last injection received over the same period in order to capture a more recent behaviour.
8
9

10 Second, cross-sectional design is known to obscure the outcome-exposure relationship in terms
11
12
13 of their timing of occurrence. However, these PLWH were mostly prevalent cases – 92% of
14
15
16
17 PLWH had been diagnosed more than two years prior (result not shown) – who were most likely
18
19
20 got infected during the early 90's through unsafe sexual behaviours and not through unsafe
21
22
23 injection practices. Lastly, because we took into account not only both provider of the last
24
25
26
27 injection or infusion received within the past year, but also facility types at which these medical
28
29
30 procedures were given in order to define unsafe injection/infusion practice, village providers
31
32
33 were considered unsafe only if they performed injection/infusion at their home or patient's home.
34
35
36
37 Although this might have underestimated the proportion of these unsafe medical procedures
38
39
40 among our study participants (as we were not able to ascertain that all village providers or
41
42
43 another person who offered medical injection/infusion in private settings – which we considered
44
45
46
47 safe – had actually undergone proper medical training to provide such procedures), the
48
49
50 combination of both provider and facility types still better captured the safety aspect of medical
51
52
53
54
55
56
57
58
59
60

1
2
3 injection/infusion than just considering each one of them separately. Besides, private clinics and
4
5
6 hospitals in Cambodia are generally considered “formal” providers.
7
8
9

10 **Implications on policy and practices**

11
12
13 Better access to medical care is a challenge particularly in rural parts of LMICs and in
14
15
16 Cambodia, it is no different. Our findings suggest the need to pull resources toward universal
17
18
19 health coverage and educational programs on safe medical injection practices. Resources are
20
21
22 always divided among many priorities in LMICs, therefore, support development partners and
23
24
25 organizations play important roles in addressing these health needs. Besides these infrastructures
26
27
28 for better healthcare access, other important programs or activities educating could be very
29
30
31 beneficial for both patients and the general population. The care providers could be an important
32
33
34 role models in enforcing correct practices when it comes to medical injection practices. In the
35
36
37 setting of HIV/AIDS care in Cambodia, counsellors could potentially play that role. Several HIV
38
39
40 health facilities offered a digital platform of communication, on a voluntary basis, to patients and
41
42
43 care providers to interact with one another or with each other, on their HIV-related issues. These
44
45
46 platforms could also be used as forums for speaking and educating our patients who are in care
47
48
49
50
51 of safe injection practices. In addition to all of these, further investigations on the injection
52
53
54
55
56
57
58
59
60

1
2
3 practices from the care provider side and the benefits or usefulness of the above educational
4
5
6
7 platforms would provide a more complete picture of the practices of medical injections in
8
9
10 Cambodia and evidence as to whether they are beneficial or if additional programs are to be put
11
12
13 in place.
14
15

16 **Conclusions**

17
18
19
20 The majority of Cambodian population, including those who are living with HIV, regard
21
22
23 medical injections and infusions as a symbol for optimal medical care. This perception and
24
25
26 injection seeking behaviours were as common in the provinces as in the capital city although
27
28
29 provinces in the central and north-eastern parts of the country seemed to exhibit extremely high
30
31
32 prevalence of unsafe medical injection practices. Although on average, they might have received
33
34
35 slightly fewer number of annual injections, PLWH were more likely to have received unsafe last
36
37
38 injection/infusion within the past year. This practice poses harms to themselves as well as their
39
40
41 community and needs to be addressed among all stakeholders including providers who are able to
42
43
44 prescribe medical injections including infusions. Our findings also suggested the need to evaluate
45
46
47 and reinforce safe injection practices among our health workers for a complete assessment and
48
49
50 understanding of medical injection education and practices in our health system.
51
52
53
54
55
56
57
58
59
60

Contributors

KS conducted literature search and data analysis, interpreted results, wrote the manuscript, and created figures. KK and KV conducted literature search, designed the study, collected the data and guided data interpretation. D.K. conducted literature search and collected the data. VS and PG conceptualized the study, conducted literature search, interpreted results and guided data interpretation. All authors provided critical feedback and shaped the final manuscript.

Funding

This work was supported by the UCLA Centre for AIDS Research/AIDS Institute grant # 5P30 AI28697.

Competing interests

None declared.

Patient consent for publication

Not applicable.

Data availability statement

The data used to support the findings of this study are available from the corresponding author upon request.

Ethics approval

Written consent was obtained from each participant before the enrolment and interview process. All interviews were conducted in a private room at the health centres/clinics. All

1
2
3 instruments used for data collection were anonymous; no identifying information, such as name,
4
5
6
7 address, telephone number, or date of birth was recorded. The HIV-related information, such as
8
9
10 ART regimen and duration of HIV infection, were obtained from linking the patient's ART code
11
12
13 to the national HIV database. The ART code for each patient is given by the HIV clinics once the
14
15
16 patients are linked to care and is used as their identifier instead of their name in the national
17
18
19 database. After the dataset had been linked, the ART code had been removed for all participants.
20
21
22
23 The study data was stored on a personal computer, keyword-protected. The study protocol was
24
25
26 approved by the University of California Los Angeles Institutional Review Board (UCLA-IRB#
27
28
29 16-000876) and the National Ethics Committee for Human Research (NECHR) of Cambodia
30
31
32
33 (NECHR# 320) in 2016.
34
35
36

37 **References**

- 38
39
40 1. World Health Organization. WHO guideline on the use of safety-engineered syringes for
41
42 intramuscular, intradermal and subcutaneous injections in health care settings. Geneva: World
43
44 Health Organization, 2016.
45
46
47 2. World Health Organization. Injection Safety: Questions and Answers. 2016.
48
49 https://www.who.int/infection-prevention/publications/is_questions-answers.pdf?ua=1 (July
50
51 2020, date last accessed).
52
53
54 3. Altaf A. Unsafe Injection Practices by Medical Practitioners in South Asia Associated with
55
56 Hepatitis and HIV Outbreaks. *J Infectiology* 2018;1(2):1-3.
57
58
59
60

- 1
2
3
4
5 4. Gupta E, Bajpai M, Sharma P, Shah A, Sarin S. Unsafe injection practices: a potential
6 weapon for the outbreak of blood borne viruses in the community. *Ann Med Health Sci Res.*
7 2013;3(2):177-81.
8
9
- 10
11
12 5. World Health Organization. Make Smart Injection Choices: National Decision-Making for
13 Safe and Appropriate Injections. 2017. [https://www.who.int/infection-](https://www.who.int/infection-prevention/tools/injections/IS_medical-treatment_leaflet.pdf?ua=1)
14 [prevention/tools/injections/IS_medical-treatment_leaflet.pdf?ua=1](https://www.who.int/infection-prevention/tools/injections/IS_medical-treatment_leaflet.pdf?ua=1) (July 2020, date last accessed).
15
16
17
- 18
19 6. Rouet F, Nouhin J, Zheng DP, Roche B, Black A, Prak S, et al. Massive Iatrogenic
20 Outbreak of Human Immunodeficiency Virus Type 1 in Rural Cambodia, 2014-2015. *Clin Infect*
21 *Dis.* 2018;66(11):1733-41.
22
23
24
- 25
26 7. Saphonn V, Fujita M, Samreth S, Chan S, Rouet F, Khol V, et al. Cluster of HIV Infections
27 Associated With Unsafe Injection Practices in a Rural Village in Cambodia. *J Acquir Immune*
28 *Defic Syndr.* 2017;75(3):e82-e6.
29
30
31
- 32
33 8. National Institute of Statistics; Directorate General for Health; and ICF International.
34 Cambodia Demographic and Health Survey 2014. Phnom Penh, Cambodia, and Rockville,
35 Maryland, USA: National Institute of Statistics; Directorate General for Health; and ICF
36 International; 2015.
37
38
39
- 40
41 9. Vong S, Perz JF, Sok S, Som S, Goldstein S, Hutin Y, et al. Rapid assessment of injection
42 practices in Cambodia, 2002. *BMC public health.* 2005;5:56.
43
44
- 45
46 10. amFAR. HIV and Comorbidities: The Foundation for AIDS Research (amFAR); 2020.
47 <https://www.amfar.org/hiv-and-comorbidities/> (July 2020, date last accessed).
48
49
- 50
51 11. World Health Organization. Chronic comorbidities and coinfections in PLHIV.
52 <https://www.who.int/hiv/topics/comorbidities/about/en/> (July 2020, date last accessed).
53
54
55
56
57
58
59
60

1
2
3
4 12. Pheng P, Meyer L, Segeral O, Chea P, Yi S, Tuot S, et al. Hepatitis C seroprevalence
5 among people living with HIV/AIDS and pregnant women in four provinces in Cambodia: an
6 integrated bio-behavioral survey. *BMC Infect Dis.* 2022;22(1):177. Epub 2022/02/24. doi:
7 10.1186/s12879-022-07163-2. PubMed PMID: 35193496; PubMed Central PMCID:
8 PMCPMC8862396.
9
10
11

12
13
14 13. Janjua NZ, Butt ZA, Mahmood B, Altaf A. Towards safe injection practices for prevention
15 of hepatitis C transmission in South Asia: Challenges and progress. *World J Gastroenterol.*
16 2016;22(25):5837-52.
17
18
19

20 14. Ministry of Health/National Center for HIV/AIDS, Dermatology and STDs
21 (MOH/NCHADS). Annual Report 2016. National Center for HIV/AIDS, Dermatology and STDs.
22 2017.
23
24

25 **Figure legends and captions**

26 *Figure 1*

27
28
29 Caption: Figure 1. Injection and infusion use among study participants by types of facility.
30
31


32 *Figure 2*

33
34 Caption: Figure 2. Injection and infusion use among study participants by residence location –
35 Phnom Penh vs provinces
36
37

38 *Figure 3*


39
40 Legend: Note: West: Pursat; North-west: Siem Reap, Battambang, Odor Meanchey, Banteay
41 Meanchey; South: Takeo, Kampot, Prey Veng; South-central: Phnom Penh, Kampong Speu;
42 South-west: Sihanoukville, Koh Kong; East: Kratie, Mondulkiri; South-east: Tbong Khmum,
43 Svay Rieng, Kampong Cham, Kandal; Central: Kampong Thom, Kampong Chhnang; North-
44 east: Steung Treng; North: Preah Vihear
45
46
47
48

49 Caption: Figure 3. Injection and infusion use among study participants by geographic distribution.
50
51
52
53
54
55
56
57
58
59
60




% of participants having had last injection/infusion (past 12 month)
 For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



Source: data from the 2017 Medical Injection Study (N=500), Cambodia



Proportion of respondents with each characteristic



For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Section in manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Abstract/Methods
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Background
Objectives	3	State specific objectives, including any prespecified hypotheses	Background/Paragraph 5
Methods			
Study design	4	Present key elements of study design early in the paper	Methods/Study design, sampling and recruitment subheading/Page 6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Methods/Study setting subheading/ Page 6
Participants	6	(a) <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	Methods/Study design, sampling and recruitment subheading and Inclusion and exclusion criteria subheading/Page 6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Methods/Definition and classification subheading/Page 8
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Methods/page 8
Bias	9	Describe any efforts to address potential sources of bias	Discussion/Page 15-16
Study size	10	Explain how the study size was arrived at	Methods/Study design, sampling and recruitment subheading/Page 6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Results/Page 10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Method/Statistical analysis subheading/Page 8
		(b) Describe any methods used to examine subgroups and	N/A

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

interactions

(c) Explain how missing data were addressed

Missingness occurred
in less than 10%
across the majority of
variables (except
income).

(d) *Cross-sectional study*—If applicable, describe analytical
methods taking account of sampling strategy

N/A

(e) Describe any sensitivity analyses

N/A

Continued on next page

For peer review only

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Methods/Study design, sampling and recruitment subheading/Page 5
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Result/Page 7-8
		(b) Indicate number of participants with missing data for each variable of interest	Result/Page 8
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	Result/Page 9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Results/Page 13
		(b) Report category boundaries when continuous variables were categorized	Result/Page 8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	Discussion/ Paragraph 2
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Discussion/Page 16-17
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Discussion
Generalisability	21	Discuss the generalisability (external validity) of the study results	Discussion/Paragraph 5
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Funding/Page 19

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

<http://www.annals.org/>, and *Epidemiology* at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only

BMJ Open

Behavioural Survey on Medical Injection and Infusion Practices among HIV-seronegative and People Living with HIV (PLWH) in 10 HIV Testing and Opportunistic Infections/Antiretroviral Therapy (OI/ART) Sites in Cambodia

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-065026.R1
Article Type:	Original research
Date Submitted by the Author:	23-Aug-2022
Complete List of Authors:	Seang, Kennarey; University of Health Sciences Khim, Keovathanak; The University of Melbourne, Nossal Institute for Global Health Vyas, Kartavya; Emory University, Epidemiology Khuon, Dyna; University of Health Sciences Faculty of Medicine Saphonn, Vonthanak; University of Health Sciences Gorbach, Pamina; University of California Los Angeles, Department of Epidemiology
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	HIV/AIDS
Keywords:	Epidemiology < INFECTIOUS DISEASES, HIV & AIDS < INFECTIOUS DISEASES, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Behavioural Survey on Medical Injection and Infusion Practices among HIV-seronegative and**
5 **People Living with HIV (PLWH) in 10 HIV Testing and Opportunistic Infections/Antiretroviral**
6 **Therapy (OI/ART) Sites in Cambodia**
7
8
9
10
11
12

13 Kennarey Seang^{1*}, Keovathanak Khim², Kartavya Vyas³, Dyna Khuon¹, Vonthanak Saphonn^{1§}
14 and Pamina Gorbach^{4§}
15
16
17
18

19 ¹ University of Health Sciences, Phnom Penh, Cambodia
20

21 ² National Institute of Public Health – School of Public Health, Phnom Penh, Cambodia
22

23 ³ Department of Epidemiology, Emory University, Atlanta, USA
24

25 ⁴ Department of Epidemiology, University of California Los Angeles, Los Angeles, USA
26
27

28 * Corresponding author: Kennarey Seang
29

30 73 Monivong Boulevard
31

32 Phnom Penh, 12201, Cambodia
33

34 Email: seang.kennarey@gmail.com
35
36
37
38
39
40
41

42 §Joint last authors.
43
44
45
46

47 E-mail addresses of authors:
48

49 KS: seang.kennarey@uhs.edu.kh | seang.kennarey@gmail.com
50

51 KK: kkvathanak@gmail.com
52

53 KV: kartavya.vyas@gmail.com
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DK: khuondyna@yahoo.com

VS: vonthanak@uhs.edu.kh

PMG: pgorbach@ucla.edu

Keywords: injection, PLWH, unsafe injection, HIV, injection prevalence, injection practices

For peer review only

Abstract

Objectives: In late 2014, an HIV outbreak occurred in rural Cambodia among villagers who received medical injections from unlicensed medical providers, justifying the need to assess medical injection practices among those who are at risk of acquiring and/or transmitting HIV. This study examined medical injection/infusion behaviours among people living with HIV (PLWH) and those who were HIV-negative in Cambodia. These behaviours should be properly assessed, especially among PLWH, as their prevalence might influence a future risk of other outbreaks.

Design: A cross-sectional survey was conducted in order to examine injection behaviours and estimate the injection prevalence and injection rates by HIV status. Unsafe injections/infusions were those received from village providers who do not work at a health centre or hospital, or traditional providers at participant's (self-injection included) or provider's home. Logistic regression was performed to examine the relationship between unsafe injection/infusion and HIV, adjusting for sex, age, education, occupation, residence location, and other risk factors.

Setting: The survey was conducted in 10 HIV testing and treatment hospitals/clinics across selected provinces in Cambodia, from February to March, 2017.

1
2
3
4 **Participants:** A total number of 500 volunteers participated in the survey, 250 PLWH and 250
5
6
7 HIV-negative individuals.

8
9
10 **Primary and secondary outcome measures:** Measures of injection prevalence and other risk
11
12
13
14 behaviour were based on self-reports.

15
16
17 **Results:** Although 47% of ($n=66$) PLWH reported comparable past year's injection/infusion use
18
19
20 to the HIV-negative participants, 54% ($n=110$) ($P=.24$), 15% ($n=11$) of PLWH reported having
21
22
23 received unsafe last injection compared to only 7% ($n=11$) of HIV-negative participants. In
24
25
26
27 logistic regression, PLWH were more likely to have had an unsafe last injection/infusion,
28
29
30 aOR=1.84 (95% CI: 0.71-4.80).

31
32
33
34 **Conclusions:** The inclination for medical injections and infusions (unsafe at times) among
35
36
37 PLWH in Cambodia was a common practice and could possibly represent yet another
38
39
40 opportunity for parenteral transmission outbreak.
41
42
43
44
45
46

47 **Strengths and limitations of this study**

48
49

- 50 • Medical injection and infusion practices assessed through self-reports could lead to bias.
- 51
52
53
54
55
56
57
58
59
60

- Only PLWH' injection and infusion practices had been assessed in this study, understanding the prescription tendencies of care providers would help complete the whole picture.
- Reverse causation, one of the biggest issues in cross-sectional study, is unlikely in our study.
- In Cambodian setting, injection and infusion practices need to account for the types of facility at which these practices are carried out in order to confirm the extent to which these practices could be interpreted as safe, which was exactly what we did in the study.

Introduction

The World Health Organization (WHO) considered over or unnecessary use of injections as unsafe injection practices, alongside the use of unsafe methods for injection, such as reusing syringe and needles [1, 2]. In some parts of the world, particularly in low- and middle-income countries (LMICs), this common medical procedure is being performed daily using unsafe (yet avoidable) injection practices which put both PLWH and communities at risk of bloodborne pathogen transmission [1-5]. In late 2014, a rural community in Cambodia had a large outbreak

1
2
3 of human immunodeficiency virus (HIV) when an unlicensed medical practitioner infected 242
4
5
6
7 villagers aged between 2 and 89 years through his use of contaminated injection equipment [6,
8
9
10 7]. In early 2018, another two HIV outbreaks linked with unsafe injection practices occurred in
11
12
13 India and Pakistan [3]. In Iran, the behavioural survey among people who inject drugs (PWID)
14
15
16 demonstrated a positive correlation between risky and unsafe injection and high prevalence of
17
18
19 HIV among them [8]. These incidents and reports demonstrated the ongoing risk of outbreaks
20
21
22 related to unsafe medical injection practices in many parts of the world. Additionally, a review
23
24
25 article on injection practices worldwide published in 2000 reckoned that many injections are
26
27
28 unsafe and unnecessary and that the region with the highest unsafe practice (reuse of injection
29
30
31 materials) was indeed in South-East Asia [9].
32
33
34
35
36

37 In Cambodia, private health care providers are commonly sought for care. Although
38
39
40 many of them are public healthcare workers who practice privately during off-working hours,
41
42
43 there are also providers, mainly in rural areas, who are unlicensed private practitioners from
44
45
46 whom the community seeks medical care including (but not limited) to injections and infusions.
47
48
49 This is not uncommon in some parts of LMICs in which a person without proper training or
50
51
52 education in administering certain medical procedures provides medical injections [4].
53
54
55
56
57
58
59
60

1
2
3
4 The last Cambodia Demographic and Health Survey (Cambodia DHS 2014) assessed
5
6
7 injection practices as part of their behavioural survey among the general population. According
8
9
10 to their report, the prevalence of medical injection (having had any medical injections from
11
12
13 health worker in the past 12 months) among the Cambodian population aged 15-49 was
14
15
16 approximately 35% (or 37% and 27% among women and men, respectively) [10]. Previous
17
18
19 studies on injection use and safety practices (including the DHS survey) in Cambodia usually
20
21
22 focused on the general population [11]. Moreover, although according to the 2019 review on
23
24
25 injection practices using the DHS data from 40 countries reported reduced numbers of unsafe
26
27
28 injections in 81% of the countries, the data used was from 2011-2015 [12], no other assessment
29
30
31 had been reported since then. Until the present work, these behavioural risk factors have not been
32
33
34 studied among people living with HIV (PLWH), despite the fact that the risk of getting or
35
36
37 transmitting bloodborne pathogens among this population are heavily shaped by these
38
39
40 behaviours. We hypothesized that PLWH might be seeking or receiving more medical injections
41
42
43 (likely unnecessary and unsafe) than the general population for several reasons. First, being in
44
45
46 regular care gives PLWH more opportunities to get diagnosed with various medical conditions
47
48
49 and receive treatments. Second, PLWH often suffer from significantly more co-morbidities, such
50
51
52
53
54
55
56
57
58
59
60

1
2
3 as age-related non-communicable diseases and mental or neurological disorders, than the general
4
5
6
7 population [13, 14]. For these reasons, PLWH might be in greater need of medical treatments,
8
9
10 such as injections, than the general population.
11
12

13
14 Ever since the 2014 HIV outbreak in Roka village, there have been no other studies
15
16 assessing injection behaviours among PLWH elsewhere; and the Cambodia DHS reported only
17
18 medical injections given by health care workers. Without assessment of injection and infusion
19
20 practices in people who are at risk of transmitting and acquiring HIV, it is challenging for public
21
22 health professionals to advise or prepare public health measures which are both appropriate and
23
24 efficient to address unsafe injection practices. Our study aims to primarily characterize injection
25
26 practices among PLWH and those who were HIV-negative and determine whether the first group
27
28 were more likely to seek unsafe or unnecessary medical injections.
29
30
31
32
33
34
35
36
37
38
39

40 Although when considering unsafe medical injections, people usually refer to used
41
42 syringes and needles, we considered (in this paper) injections provided by unlicensed (medical)
43
44 practitioners unsafe as well. Understanding these injection seeking behaviours among this
45
46
47 population is helpful for planning necessary public health measures as well as improving access
48
49
50
51 to formal healthcare facilities.
52
53
54
55
56
57
58
59
60

Methods

Study design and setting

We conducted a cross-sectional study among PLWH ($n=250$) who came to receive their HIV treatment care and those who came to have HIV testing and had a negative result ($n=250$) at 10 selected HIV clinics in five provinces and the capital city (Phnom Penh) of Cambodia, from early February to the end of March 2017. The sample size of 250 per group was calculated to provide 90% power to test the hypothesis using a two-sample comparison of proportions where the first proportion was set at 20% of injection use (HIV-negative participants) and the second proportion was set at 35% (HIV-positive participants). In Cambodia, HIV voluntary testing sites in Cambodia and HIV/AIDS treatment and care clinics (called Opportunistic Infections/Antiretroviral Therapy (OI/ART) sites) and are under the supervision of the National Centre for HIV/AIDS, Dermatology and STD (NCHADS); there are around 52 of them across Cambodia at the time of the study.

A two-stage sampling approach was employed for participant selection. We selected 10 sites and out of the 52 sites with joint testing/OI/ART services (meaning those with both testing and OI/ART services) using probability-proportional-to-size (PPS) method. Then, from each of

1
2
3 these 10 sites, we consecutively sampled 25 PLWH who came for their regular clinic visit or
4
5
6 pharmacy refill. In a similar manner, HIV-negative individuals who came to each selected sites
7
8
9
10 for HIV testing who got a negative result were approached for recruitment (25 per site).
11
12

13 **Inclusion and exclusion criteria**

14
15
16 Both PLWH and HIV-negative participants were eligible if they were at least 18 years
17
18
19 old and were willing and able to provide written informed consent to take part in the study on the
20
21
22 data collection day. Excluded were individuals who are not willing or able to complete the
23
24
25 questionnaire, had undetermined test result, or presented any other condition that, in the opinion
26
27
28 of the research or local healthcare staff, would preclude informed consent.
29
30
31
32

33 **Medical history and behavioural assessment**

34
35
36 HIV-specific factors (HIV status and date of HIV test, WHO disease stage, etc.) were
37
38
39 obtained from linkage with the NCHADS database. Behavioural data were collected using a
40
41
42 Computer-Assisted Person Interview (CAPI) technique, administered via tablet and questions
43
44
45 were guided by literature. Participants were asked to report on socio-demographic factors, such
46
47
48 as date of birth, sex, education, marital status, occupation, general location of residence (village,
49
50
51 community, district and province) and a wide range of behavioural factors including history of
52
53
54
55
56
57
58
59
60

1
2
3 illicit injection drug use (IDU), alcohol and tobacco use, informal medical injection/infusion use,
4
5
6
7 such as frequency, and type of provider.
8
9

10 **Definition and classification**

11
12
13 The outcome of interest, unsafe medical injection (binary outcome), was defined as
14
15
16 having received last injection or infusion (within the past year) from village providers who do
17
18
19 not work at health centre or hospital, from traditional providers, or by self-injection (other than
20
21
22 diabetic medication) either at their own home or at the provider's home. In Cambodia and
23
24
25 especially in rural areas, these health workers might also provide some basic medical services
26
27
28 (including injections and infusions) at their patient's home or in private hospitals/clinics.
29
30
31

32
33
34 Therefore, regardless of where the PLWH receive the injections, as long as they were provided
35
36
37 by the providers who work at hospital or health centre, we considered these injections safe. Both
38
39
40 intravenous and intramuscular injections were included in the questionnaire and reporting.
41
42
43

44 The prevalence of medical injections counted those who reported at least one injection or
45
46
47 infusion (over the past year), but excluded vaccinations, non-medical injections and rare medical
48
49
50 injections such as transfusion.
51
52
53
54
55
56
57
58
59
60

1
2
3
4 The HIV status was not assessed by the study team, those with known HIV-positive or
5
6
7 HIV-negative result were informed of the present study and referred to study team for further
8
9
10 information on the study and consent process from their care providers, we had no access to their
11
12
13 HIV test or result.
14

15
16
17 Other risk behavioural assessment (alcohol and tobacco use, informal medical
18
19
20 injection/infusion use, etc.) was based on participants' self-report.
21
22

23 **Statistical analysis**

24
25
26
27 We computed percentages and means of the key characteristics by HIV status. We
28
29
30 calculated the prevalence of having had at least one medical injection from health workers and
31
32
33 from all provider types over the past year among the participants (by their HIV status). Chi-
34
35
36 square and Exact tests were used for categorical variables and t-test for continuous variables.
37
38
39
40 Next, the average number of past year's medical injections from each type of providers by HIV
41
42
43 status was also computed and we reported the *P* derived from Poisson regression. Finally, to
44
45
46
47 examine the relationship between unsafe medical injection practices and HIV status, we
48
49
50 performed a logistic regression, adjusting for sex, age, education, occupation, residence location,
51
52
53 injection preference and other risk factors. Confounding variables were based on prior
54
55
56
57
58
59
60

1
2
3
4 knowledge and literature review on similar work previously conducted. All analyses were done
5
6
7 in STATA 14.
8
9

10 **Patient and public involvement**

11
12
13 The PLWH, care givers and those who sought HIV testing but were negative participated
14
15
16 in the data collection of the study. Preliminary results of the study had been presented at the
17
18
19 University of Health Sciences at the 2018 Scientific Days among invited care givers, students
20
21
22 and other invited guests and researchers.
23
24
25

26 **Results**

27
28
29 We presented key characteristics by HIV status in Table 1. [Insert Table 1 here] The
30
31
32 socio-demographic factors are vastly different between the two groups in terms of age, marital
33
34
35 status, educational background and occupation. PLWH appeared to be much older – mean age
36
37
38 was 43 years (SD 9), of a lower educational background and married, while the majority of HIV-
39
40
41 negative participants were younger – mean age was 31 years (SD 11), more educated and single.
42
43
44 However, both groups were comparable in terms of their sex, income and residence location
45
46
47
48
49
50
51 distribution. Female participants accounted for about 66% ($n=164$) of PLWH and 71% ($n=177$)
52
53
54
55
56
57
58
59
60

of those uninfected. The majority of participants from both groups were from the provinces, 91% ($n=227$) among PLWH and 93% ($n=231$) among the uninfected.

Table 1. Key characteristics of study participants by HIV status, Informal Medical Injection

Study ($n=500$), Cambodia, 2017

Socio-demographics	HIV+		HIV-		<i>P</i>
	<i>(n=250)</i>		<i>(n=250)</i>		
	<i>n</i>	<i>%</i>	<i>n</i>	<i>%</i>	
Gender					
Female	164	65.6	177	70.8	.21
Male	86	34.4	73	29.2	
Age ^a (Mean, SD)	(43.1, 9.0)		(30.6, 10.7)		<.001
Marital status					
Single	15	6.0	87	34.8	<.001
Married	140	56.0	141	56.4	
Divorced	41	16.4	15	6.0	
Widowed	54	21.6	7	2.8	
Education					
Secondary or higher	104	41.6	163	65.2	<.001
Primary or less	146	58.4	87	34.8	
Occupation ^a					
Unemployed	81	32.7	126	50.8	<.001
Self-employed/farmers	95	38.3	70	28.2	
Employed	72	29.0	52	21.0	
Household annual income ^{a,b} (USD)					
> 3,000	40	22.9	44	22.8	.48
1,800-3,000	45	25.7	42	21.8	
1,001-1,800	39	22.3	56	29.0	
≤ 1,000	51	29.1	51	26.4	
Current address ^a					
Province	227	90.8	231	92.8	.42

Phnom Penh (capital city)	23	9.2	18	7.2	
Other behavioural risk factors ^c					
Smoke monthly or more often	30	12.0	13	5.2	<.01
Feeling drunk at least once a month	45	18.0	63	25.2	.05
Contact with syringe and needle at workplace	8	3.2	36	15.5	<.01
Had at least one hospitalization	42	23.5	87	49.2	<.001

SD, Standard Deviation.

^aMissing (HIV+, HIV-, respectively): age ($n=5$, $n=5$); occupation ($n=2$, $n=2$); current address ($n=0$, $n=1$).

^bThe categories for household income used quartiles to assure sufficient numbers in each category.

^cSelf-report over the past year.

Injection/infusion use

Injection and infusion practices are described in Table 2. [Insert Table 2 here] We found that the average annual number of injection/infusion from health workers was about three and four injections per person among PLWH and those who were HIV-negative, respectively ($P<.001$). The prevalence of any medical injection/infusion provided by health workers over the past year was higher among HIV-uninfected participants, 72% ($n=153$), compared to 40% ($n=61$) among those who were HIV-positive ($P<.001$). However, the prevalence of past year's injection/infusion from all providers between the two groups were comparable, 47% ($n=66$) among PLWH and 54% ($n=110$) among those uninfected ($P=.24$).

Table 2. Injection and infusion seeking behaviours of study participants by HIV status, Informal Medical Injection Study ($n=500$), Cambodia, 2017

Injection and infusion practices	HIV+ ($n=250$)		HIV- ($n=250$)		<i>P</i>
	<i>n</i>	%	<i>n</i>	%	
Injection and infusion received					
Last injection/infusion within past year					
Given by relative/acquainted provider	51	23.0	50	22.8	.97
Recommended by provider	54	85.7	131	90.3	.33
Given at public hospital	35	44.9	97	54.5	.16
Given at private hospital/clinic	29	53.7	58	46.0	.35
Given at their own home	16	31.4	24	21.2	.16
Number of injections/infusions within past year					
More than a year ago	107	67.7	144	66.4	.78
From health workers (mean, SD)		(3.2, 7.5)		(4.3, 7.1)	<.001
From all providers (mean, SD)		(3.5, 7.1)		(4.4, 7.8)	<.001
At least one - health worker	61	40.4	153	72.5	<.001
At least one - all providers	66	47.5	110	53.9	.24
Prefer injection to other treatments ^a	124	49.6	145	58.0	.06
Injection and infusion safety					
Last injection within past year					
Unsafe ^b last injection	11	15.5	11	7.3	.06
Provider did not use new, unopened syringe/needle	0	0.0	6	3.8	.19
Last injection within past year					
Unsafe ^b last infusion	10	13.5	13	10.5	.52
Provider did not use new, unopened syringe/needle	0	0.0	3	2.5	.55

SD, Standard Deviation.

^aThe questions on this preference pertain to several tracer conditions (in which case medical injections are clearly unnecessary).

^bAdministered at participant's or provider's home by village providers who do not work at health centre or hospital, traditional providers, or self-injection.

When asked about the last injection/infusion they received within the past year, PLWH were more likely to report having received their last one(s) at a private hospital/clinic, 54 % ($n=29$), or at their own home, 31% ($n=16$), compared to a 46% ($n=58$) and 21% ($n=24$), respectively, reported by their HIV-negative counterparts. HIV-negative participants were more likely to have received their last injection/infusion at a public hospital, 54% ($n=97$), as opposed to 45% ($n=35$) of PLWH ($P=.16$). Figure 1 broke down last injection and infusion by facility types in more details. [Insert Figure 1 here]

Regardless of HIV status, public and private sector accounted for the majority of medical injection and infusion received. Although none of our PLWH reported having received their last injection or infusion at traditional healer's home, about one-fourth of them reported having received their last injection (15% ($n=9$)) and infusion (22% ($n=14$)) at their own home.

A large number of participants from both groups, 50% ($n=124$) of PLWH and 58% ($n=145$) of those uninfected, reported that they preferred injection/infusion to other forms of treatment when sick ($P=.06$). Moreover, more than 60% of participants from both groups

1
2
3 indicated that they had actually received more injections the past year than previous year.
4
5

6
7 Similarly, over 80% of both PLWH and HIV-negative participants reported that their last
8

9
10 injection was in fact recommended by their care provider.
11
12

13 **Injection/infusion safety practices**

14
15
16
17 About 4% ($n=6$) of HIV-negative participants reported that the provider for their last
18
19
20 injection did not use a new, unopened package of syringe and needles while none of PLWH
21
22
23 reported this practice ($P=.06$). Although the average annual injection/infusion rates from all
24
25
26 provider types (including health workers) were slightly lower among PLWH (three injections per
27
28
29 person) compared with those who were HIV-negative (four injections per person) ($P<.001$), we
30
31
32 observed a slightly larger proportion of PLWH reported an unsafe last injection within the past
33
34
35 year, 15% ($n=11$) vs 7% ($n=11$) reported by those who were HIV-negative ($P=.06$). Likewise,
36
37
38 13% ($n=10$) of PLWH reported an unsafe last infusion within the past year, compared to 10%
39
40
41
42
43 ($n=13$) of HIV-uninfected participants ($P=.52$). Regardless of whether they live in the provinces
44
45
46 or the capital city “Phnom Penh” (Figure 2), the majority of participants from both groups
47
48
49 reported their provider recommended their last injection/infusion and more HIV- participants
50
51
52
53 than PLWH received their last injection/infusion from health workers. [Insert Figure 2 here] In
54
55
56
57
58
59
60

1
2
3 figure 3, overall, we saw similar patterns across the country, except provinces in the central and
4
5
6
7 north-eastern parts of Cambodia where injection/infusion use appeared the highest. [Insert Figure
8
9
10 3 here]
11
12

13 Association between unsafe medical injection/infusion and HIV

14
15
16
17 Table 3 presents the crude, adjusted OR and the 95% CI of the relationship between
18
19
20 unsafe last medical injection and HIV status. [Insert Table 3 here] Before adjustment, only sex,
21
22
23 occupation and presence of two or more risk behaviours were associated with having had unsafe
24
25
26 last injection or infusion (Table 3). HIV status appeared to be positively associated with unsafe
27
28
29 medical injection/infusion, cOR=1.45 (95% CI: 0.70-3.00). After adjusting for other covariates,
30
31
32
33
34 PLWH were almost twice more likely to have had an unsafe last injection or infusion than those
35
36
37 who were HIV-negative, aOR=1.84 (95% CI: 0.71-4.80).
38
39

40
41 Table 3. Association between getting unsafe medical injection and HIV status, Informal Medical
42
43
44 Injection Study ($n=500$), Cambodia, 2017
45
46

47 Outcome: unsafe injection/infusion	48 Crude OR	49 95 % CI	Adjusted OR ^a	95 % CI
50 HIV + (ref. HIV-)	1.45	0.70-3.00	1.84	0.71-4.80
51 Male (ref. female)	2.17	1.03-4.57	2.37	1.00-5.62
52 Age	1.00	0.97-1.03	0.98	0.94-1.02
53 Education (ref. secondary or higher)				

Primary or less	0.70	0.33-1.46	0.96	0.41-2.23
Occupation (ref. unemployed)				
Farmers and self-employed	0.91	0.41-2.01	0.83	0.36-1.91
Employed	0.48	0.17-1.36	0.59	0.20-1.72
Current address in Phnom Penh (ref. in provinces)	1.18	0.33-4.23	1.02	0.27-3.88
Prefer injection or infusion when sick (ref. no preference)	0.59	0.29-1.21	0.66	0.32-1.40
Had at least two risk behaviours ^b	0.67	0.19-2.33	0.47	0.13-1.75

CI, Confidence Interval.

Unsafe injection/infusion: last injection/infusion within the past year administered at participant's or provider's home by village providers who do not work at health centre or hospital, traditional providers, or self-injection.

^aAdjusted for gender, age, education, occupation, residence location, injection or infusion preference, and presence of two or more risk behaviours.

^bCombination of risk behaviours include: one or more hospitalization, contact with syringe and needle, smoking monthly or more often and feeling drunk monthly or more often in the past year.

Discussion

In our study, we found a high prevalence of medical injections (having had any medical injections in the past year from health workers) among the study participants in general (almost 60%), but PLWH were more likely to have had unsafe last injection or infusion (having received their last injection from informal providers), compared with those who were HIV-negative. Regardless of the reasons for medical injections (with few exceptions), this practice is very common, and should be addressed, whether it is the PLWH's false beliefs that injectable drugs

1
2
3 work better than oral ones for certain medical conditions or the tendency to over-prescribe these
4
5
6
7 injectables.
8
9

10 According to the 2014 CDHS, there were great variations of injection prevalence
11
12
13 (administered by health workers) ranging from 12% to 45% and the average annual number of
14
15
16
17 injections is one to two per person [10]. We found a much higher prevalence among our study
18
19
20 sample, our results were more in line with an article published in 2004 by Vong et al. that also
21
22
23 looked at medical injections in Cambodia found a 40% of medical injection prevalence and
24
25
26
27 average number of injection (over the past six months) of 5.9 per person [11]. This is, in fact,
28
29
30 consistent with findings from a review paper published in 2016 which found that 12-month
31
32
33
34 medical injection prevalence ranged from 30% to 68% across studies conducted in south Asia
35
36
37 [15]. It should be noted that both the 2004 study and the 2014 DHS examined the injection
38
39
40 practices among the general population outside of HIV setting (treatment or testing), and that it
41
42
43
44 was unclear in the CDHS if infusions were also counted for their injection reporting. Our study
45
46
47 grouped infusions with injections when reporting prevalence, similar to the 2004 study (Vong et
48
49
50 al), but our study reported the injection behaviours over the past year instead of over six months
51
52
53
54 like Vong et al did. Several other factors such as limited education, tendency of prescribers to
55
56
57
58
59
60

1
2
3 recommend and participant's personal preference of injection and the study population could be
4
5
6
7 responsible for higher rates being reported in our study compared with others. However, these
8
9
10 seemed consistent with a recently published paper which found high Hepatitis C prevalence
11
12
13 among Cambodian population that is likely due to medical injections [16]. High prevalence of
14
15
16 medical injection (ranging from 30% to 68%) had also been reported across studies conducted in
17
18
19 south Asia [15]. Although slightly different from our study, results from Kenyan survey
20
21
22 published in 2016 reported a positive association between HIV and those who reported having
23
24
25 received injection in the last 12 months [17]. The Kenyan study only reported injections from
26
27
28 care providers and not traditional healers or other types of providers.
29
30
31

32
33
34 The older mean age of our PLWH might also explain the high prevalence of medical
35
36
37 injections among them. Because PLWH in the study were on average older, they could be sicker
38
39
40 and, therefore, sought more medical procedures including injections. The age distribution of
41
42
43 PLWH in Cambodia is actually weighed down by those who had been infected in the early 90's;
44
45
46 and fewer people had become infected since 2000 [18].
47
48
49

50
51 The study should be interpreted with consideration to a number of limitations. Our
52
53
54 assessment of the outcome was based on self-recall which could result in misclassification of the
55
56
57

1
2
3
4 outcome measured. However, we have limited recalls to the past 12 months and reckon that to
5
6
7 avoid capturing only certain fluctuations, a recall over 12 months appeared reasonable. Multiple
8
9
10 studies used a 12-month timeframe for estimating prevalence (although they mainly assessed
11
12
13 drug use) [19, 20]. Medical injections are generally also uncommon events, we, therefore,
14
15
16 expected this misclassification, if any, to be minimal. By design, the outcome-exposure
17
18
19 relationship in our study is obscure. However, our PLWH were mostly prevalent cases and older
20
21
22 – 92% of PLWH had been diagnosed more than two years prior (result not shown) – who were
23
24
25 most likely got infected during the early 90's through unsafe sexual behaviours and not through
26
27
28 unsafe injection practices. Consecutive sampling among PLWH and HIV-negative participants
29
30
31 could also affect our internal validity; however, the process of scheduling the appointment at
32
33
34 each selected facility for both groups is already in itself a random process. There were also
35
36
37 patients who just dropped in. In other words, there is no reason to believe that participants might
38
39
40 differ in terms of injection use between the time of our data collection and any other time. This
41
42
43 does, however, limit our own study findings' generalizability in a way that they might be
44
45
46 applicable to only PLWH and HIV-negative population who come to receive care and seek HIV
47
48
49 testing at the selected clinics and hospitals.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 The strengths of our study included the fact that we took into account not only both
5
6
7 provider of the last injection or infusion received within the past year, but also facility at which
8
9
10 these medical procedures were given, the combination of both provider and facility types should
11
12
13 be able to capture better the safety aspect of medical injection/infusion. It should be noted that
14
15
16 private facilities in Cambodia are generally considered “formal” providers. Our work is one of
17
18
19 the few studies which examined injection practices among PLWH over the past decade. Another
20
21
22 study was conducted in 2016 (a year prior to when our study had started) [16]. Regardless,
23
24
25 additional studies are necessary in order to confirm the findings from our work and understand
26
27
28 the true underlying injection practices among PLWH.
29
30
31

32 33 34 **Implications on policy and practices**

35
36
37 Better access to medical care is a challenge particularly in rural parts of Cambodia. Our
38
39
40 findings suggest the need to pull resources toward universal health coverage and educational
41
42
43 programs on safe medical injection practices. Resources are always limited in LMICs; therefore,
44
45
46 support development partners play important roles in addressing these health needs. Besides
47
48
49 these, other important educational programs or activities directed at both PLWH and HIV-
50
51
52 negative population also deemed beneficial. Care providers could be important role models in
53
54
55
56
57
58
59
60

1
2
3 enforcing correct practices of medical injection, particularly, counsellors in the setting of
4
5
6
7 HIV/AIDS care here, could also play that role. Several HIV health facilities offered a digital
8
9
10 platform of communication (Telegram group chat and Facebook Messenger chats are the most
11
12
13 commonly used), on a voluntary basis, to PLWH and care providers to interact with one another
14
15
16 or with each other, on their HIV-related issues. These platforms could also be used as forums for
17
18
19 communicating correct safe injection practices to them. Of course, these types of programs
20
21
22 would need further investigations in order to understand the population whom we could reach
23
24
25
26 with these digital platforms. Regardless of HIV status, these educational programs and activities
27
28
29 should be widely inclusive because use of medical injection seemed to be very common among
30
31
32 both PLWH and those who were HIV-negative. Nevertheless, further investigations on the
33
34
35 injection practices (among care provider) and the benefits of the aforementioned educational
36
37
38 platforms would provide a more complete picture of the practices of medical injections in
39
40
41 Cambodia and evidence as to whether they are beneficial or if additional programs are to be put
42
43
44
45
46
47 in place.
48
49

50 **Conclusions**

51
52
53
54
55
56
57
58
59
60

1
2
3
4 The majority of Cambodian population, including those who are living with HIV, regard
5
6
7 medical injections and infusions as a symbol for optimal medical care. Although on average, they
8
9
10 might have received slightly fewer number of annual injections, PLWH were more likely to have
11
12
13 received unsafe last injection/infusion within the past year. This practice poses harms to
14
15
16 themselves as well as their community and needs to be addressed among all stakeholders including
17
18
19 providers who are able to prescribe medical injections including infusions. Our findings suggested
20
21
22 the need to evaluate and reinforce safe injection practices among our health workers for a complete
23
24
25 assessment and understanding of medical injection education and practices in our health system.
26
27
28
29

30 **Contributors**

31
32
33 KS conducted literature search and data analysis, interpreted results, wrote the
34
35 manuscript, and created figures. KK and KV conducted literature search, designed the study,
36
37 collected the data and guided data interpretation. D.K. conducted literature search and collected
38
39 the data. VS and PG conceptualized the study, conducted literature search, interpreted results and
40
41 guided data interpretation. All authors provided critical feedback and shaped the final
42
43 manuscript.
44
45
46
47

48 **Funding**

49
50
51 This work was supported by the UCLA Centre for AIDS Research/AIDS Institute grant #
52
53 5P30 AI28697.
54

55 **Competing interests**

1
2
3
4 None declared.
5

6 **Patient consent for publication**
7

8 Not applicable.
9

10
11 **Data availability statement**
12

13 The data used to support the findings of this study are available from the corresponding
14 author upon request.
15

16
17
18 **Ethics approval**
19

20
21
22 Written consent was obtained from each participant before the enrolment and interview
23
24
25 process. All interviews were conducted in a private room at the health centres/clinics. All
26
27
28 instruments used for data collection were anonymous; no identifying information, such as name,
29
30
31 address, telephone number, or date of birth was recorded. The HIV-related information, such as
32
33
34
35 ART regimen and duration of HIV infection, were obtained from linking the patient's ART code
36
37
38 to the national HIV database. The ART code for each patient is given by the HIV clinics once the
39
40
41 PLWH are linked to care and is used as their identifier instead of their name in the national
42
43
44 database. After the dataset had been linked, the ART code had been removed for all participants.
45
46
47
48 The study data was stored on a personal computer, keyword-protected. The study protocol was
49
50
51 approved by the University of California Los Angeles Institutional Review Board (UCLA-IRB#
52
53
54
55
56
57
58
59
60

1
2
3 16-000876) and the National Ethics Committee for Human Research (NECHR) of Cambodia
4
5
6
7 (NECHR# 320) in 2016.
8
9

10 **References**

- 11
12
13
14 1. World Health Organization. WHO guideline on the use of safety-engineered syringes for
15 intramuscular, intradermal and subcutaneous injections in health care settings. Geneva: World
16 Health Organization, 2016.
17
18
- 19
20
21 2. World Health Organization. Injection Safety: Questions and Answers. 2016.
22 https://www.who.int/infection-prevention/publications/is_questions-answers.pdf?ua=1 (July 2020, date
23 last accessed).
24
25
26
- 27
28
29 3. Altaf A. Unsafe Injection Practices by Medical Practitioners in South Asia Associated with
30 Hepatitis and HIV Outbreaks. *J Infectiology* 2018;1(2):1-3.
31
32
33
- 34
35 4. Gupta E, Bajpai M, Sharma P, Shah A, Sarin S. Unsafe injection practices: a potential
36 weapon for the outbreak of blood borne viruses in the community. *Ann Med Health Sci Res.*
37 2013;3(2):177-81. Epub 2013/08/07. doi: 10.4103/2141-9248.113657. PubMed PMID: 23919185;
38 PubMed Central PMCID: PMC3728858.
39
40
41
42
43
- 44
45 5. World Health Organization. Make Smart Injection Choices: National Decision-Making for
46 Safe and Appropriate Injections. 2017. [https://www.who.int/infection-](https://www.who.int/infection-prevention/tools/injections/IS_medical-treatment_leaflet.pdf?ua=1)
47 [prevention/tools/injections/IS_medical-treatment_leaflet.pdf?ua=1](https://www.who.int/infection-prevention/tools/injections/IS_medical-treatment_leaflet.pdf?ua=1) (July 2020, date last
48 accessed).
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 6. Rouet F, Nouhin J, Zheng DP, Roche B, Black A, Prak S, et al. Massive Iatrogenic
5 Outbreak of Human Immunodeficiency Virus Type 1 in Rural Cambodia, 2014-2015. *Clin Infect*
6 *Dis.* 2018;66(11):1733-41. Epub 2017/12/07. doi: 10.1093/cid/cix1071. PubMed PMID:
7 29211835; PubMed Central PMCID: PMC5963970.
8
9
10
11
- 12
13 7. Saphonn V, Fujita M, Samreth S, Chan S, Rouet F, Khol V, et al. Cluster of HIV Infections
14 Associated With Unsafe Injection Practices in a Rural Village in Cambodia. *J Acquir Immune*
15 *Defic Syndr.* 2017;75(3):e82-e6. Epub 2017/01/28. doi: 10.1097/QAI.0000000000001295.
16 PubMed PMID: 28129255; PubMed Central PMCID: PMC6814627.
17
18
19
20
- 21
22 8. Esmaeili A, Shokoohi M, Danesh A, Sharifi H, Karamouzian M, Haghdoost A, et al. Dual
23 Unsafe Injection and Sexual Behaviors for HIV Infection Among People Who Inject Drugs in Iran.
24 *AIDS and behavior.* 2019;23(6):1594-603. Epub 2018/11/22. doi: 10.1007/s10461-018-2345-5.
25 PubMed PMID: 30460664; PubMed Central PMCID: PMC6527484.
26
27
28
29
- 30
31 9. Hutin YJFH, Anja M; Armstrong, Gregory L. Use of injections in healthcare settings
32 worldwide, 2000: literature review and regional estimates. *Bmj.* 2003. doi:
33 10.1136/bmj.327.7423.1075.
34
35
36
37
38
39
- 40 10. National Institute of Statistics; Directorate General for Health; and ICF International.
41 Cambodia Demographic and Health Survey 2014. Phnom Penh, Cambodia, and Rockville,
42 Maryland, USA: National Institute of Statistics; Directorate General for Health; and ICF
43 International; 2015.
44
45
46
47
48
49
- 50 11. Vong S, Perz JF, Sok S, Som S, Goldstein S, Hutin Y, et al. Rapid assessment of injection
51 practices in Cambodia, 2002. *BMC public health.* 2005;5:56. Epub 2005/06/03. doi:
52 10.1186/1471-2458-5-56. PubMed PMID: 15929800; PubMed Central PMCID:
53 PMC1173117.
54
55
56
57

- 1
2
3
4
5
6 12. Hayashi T, Hutin YJ, Bulterys M, Altaf A, Allegranzi B. Injection practices in 2011-2015:
7 a review using data from the demographic and health surveys (DHS). *BMC Health Serv Res.*
8 2019;19(1):600. Epub 2019/08/29. doi: 10.1186/s12913-019-4366-9. PubMed PMID: 31455315;
9 PubMed Central PMCID: PMCPMC6712605.
10
11
12
13
14
15 13. amFAR. HIV and Comorbidities: The Foundation for AIDS Research (amFAR); 2020.
16 <https://www.amfar.org/hiv-and-comorbidities/> (July 2020, date last accessed).
17
18 14. World Health Organization. Chronic comorbidities and coinfections in PLHIV.
19 <https://www.who.int/hiv/topics/comorbidities/about/en/> (July 2020, date last accessed).
20
21
22
23
24 15. Janjua NZ, Butt ZA, Mahmood B, Altaf A. Towards safe injection practices for prevention
25 of hepatitis C transmission in South Asia: Challenges and progress. *World J Gastroenterol.*
26 2016;22(25):5837-52. Epub 2016/07/20. doi: 10.3748/wjg.v22.i25.5837. PubMed PMID:
27 27433097; PubMed Central PMCID: PMCPMC4932219.
28
29
30
31
32
33 16. Pheng P, Meyer L, Segeral O, Chea P, Yi S, Tuot S, et al. Hepatitis C seroprevalence
34 among people living with HIV/AIDS and pregnant women in four provinces in Cambodia: an
35 integrated bio-behavioral survey. *BMC Infect Dis.* 2022;22(1):177. Epub 2022/02/24. doi:
36 10.1186/s12879-022-07163-2. PubMed PMID: 35193496; PubMed Central PMCID:
37 PMCPMC8862396.
38
39
40
41
42
43
44
45 17. Kimani D, Kamau R, Ssempijja V, Robinson K, Oluoch T, Njeru M, et al. Medical
46 injection use among adults and adolescents aged 15 to 64 years in Kenya: results from a national
47 survey. *J Acquir Immune Defic Syndr.* 2014;66 Suppl 1:S57-65. Epub 2014/01/15. doi:
48 10.1097/QAI.000000000000106. PubMed PMID: 24413041; PubMed Central PMCID:
49 PMCPMC4794988.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 18. Ministry of Health/National Center for HIV/AIDS, Dermatology and STDs
5 (MOH/NCHADS). Annual Report 2016. National Center for HIV/AIDS, Dermatology and STDs.
6 2017.
7
8
9
10 19. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global
11 prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV,
12 HBV, and HCV in people who inject drugs: a multistage systematic review. *Lancet Glob Health*.
13 2017;5(12):e1192-e207. Epub 2017/10/28. doi: 10.1016/S2214-109X(17)30375-3. PubMed
14 PMID: 29074409; PubMed Central PMCID: PMC5683738.
15
16
17
18
19
20
21
22 20. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Methodological
23 Guidelines to Estimate the Prevalence of Problem Drug Use on the Local Level. Lisbon:
24 EMCDDA, December 1999.
25
26
27

28 **Figure legends and captions**

29 *Figure 1*

30
31
32 Caption: Figure 1. Injection and infusion use among study participants by types of facility.
33
34


35 *Figure 2*

36
37 Caption: Figure 2. Injection and infusion use among study participants by residence location –
38 Phnom Penh vs provinces
39
40

41 *Figure 3*


42
43 Legend: Note: West: Pursat; North-west: Siem Reap, Battambang, Odor Meanchey, Banteay
44 Meanchey; South: Takeo, Kampot, Prey Veng; South-central: Phnom Penh, Kampong Speu;
45 South-west: Sihanoukville, Koh Kong; East: Kratie, Mondulkiri; South-east: Tbong Khmum,
46 Svay Rieng, Kampong Cham, Kandal; Central: Kampong Thom, Kampong Chhnang; North-
47 east: Steung Treng; North: Preah Vihear
48
49
50
51

52 Caption: Figure 3. Injection and infusion use among study participants by geographic distribution.
53
54
55
56
57
58
59
60




% of participants having had last injection/infusion (past 12 month)
 For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



Source: data from the 2017 Medical Injection Study (N=500), Cambodia



Proportion of respondents with each characteristic



For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Section in manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Abstract/Methods
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Background
Objectives	3	State specific objectives, including any prespecified hypotheses	Background/Paragraph 5
Methods			
Study design	4	Present key elements of study design early in the paper	Methods/Study design and setting subheading/Page 6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Methods/Study design and setting subheading/Page 6
Participants	6	(a) <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	Methods/ Study design and setting and Inclusion and exclusion criteria/Page 6-7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Methods/Definition and classification subheading/Page 7-8
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Methods/Medical history and behavioural assessment/page 7
Bias	9	Describe any efforts to address potential sources of bias	Discussion/Page 15-16
Study size	10	Explain how the study size was arrived at	Methods/Study design and setting subheading/Page 6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Results/Page 9-10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Method/Statistical analysis subheading/Page 8
		(b) Describe any methods used to examine subgroups and interactions	N/A
		(c) Explain how missing data were addressed	Missingness occurred in less than 10% across the majority of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

variables (except
income).

(d) <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	N/A
(e) Describe any sensitivity analyses	N/A

Continued on next page

For peer review only

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Methods/Study design, sampling and recruitment subheading/Page 5
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Result/Page 7-8
		(b) Indicate number of participants with missing data for each variable of interest	Result/Page 8
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	Result/Page 9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Results/Page 13
		(b) Report category boundaries when continuous variables were categorized	Result/Page 8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	Discussion/ Paragraph 2
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Discussion/Page 16-17
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Discussion
Generalisability	21	Discuss the generalisability (external validity) of the study results	Discussion/Paragraph 5
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Funding/Page 19

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

<http://www.annals.org/>, and *Epidemiology* at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only

BMJ Open

Medical injection and infusion practices among HIV-seronegative people and people living with HIV: a behavioural survey of ten HIV testing and opportunistic infections/antiretroviral therapy sites in Cambodia

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-065026.R2
Article Type:	Original research
Date Submitted by the Author:	13-Sep-2022
Complete List of Authors:	Seang, Kennarey; University of Health Sciences Khim, Keovathanak; The University of Melbourne, Nossal Institute for Global Health Vyas, Kartavya; Emory University, Epidemiology Khuon, Dyna; University of Health Sciences Faculty of Medicine Saphonn, Vonthanak; University of Health Sciences Gorbach, Pamina; University of California Los Angeles, Department of Epidemiology
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	HIV/AIDS
Keywords:	Epidemiology < INFECTIOUS DISEASES, HIV & AIDS < INFECTIOUS DISEASES, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Medical injection and infusion practices among HIV-seronegative people and**
5 **people living with HIV: a behavioural survey of ten HIV testing and opportunistic**
6 **infections/antiretroviral therapy sites in Cambodia**
7
8
9
10
11
12
13
14

15 Kennarey Seang^{1*}, Keovathanak Khim², Kartavya Vyas³, Dyna Khuon¹, Vonthanak Saphonn^{1§}
16 and Pamina Gorbach^{4§}
17
18
19
20
21

22 ¹ University of Health Sciences, Phnom Penh, Cambodia

23 ² National Institute of Public Health – School of Public Health, Phnom Penh, Cambodia

24 ³ Department of Epidemiology, Emory University, Atlanta, USA

25 ⁴ Department of Epidemiology, University of California Los Angeles, Los Angeles, USA
26
27
28
29

30 *Correspondence to:

31 Kennarey Seang
32

33 73 Monivong Boulevard, Phnom Penh, 12201, Cambodia
34
35

36 seang.kennarey@gmail.com
37
38
39
40
41
42
43
44

45 §Joint last authors.
46
47
48

49 E-mail addresses of authors:
50

51 KS: seang.kennarey@uhs.edu.kh | seang.kennarey@gmail.com
52

53 KK: kkvathanak@gmail.com
54
55
56
57
58
59
60

1
2
3
4 KV: kartavya.vyas@gmail.com
5

6 DK: khuondyna@yahoo.com
7

8 VS: vonthanak@uhs.edu.kh
9

10
11 PMG: pgorbach@ucla.edu
12
13
14
15
16
17

18 *Keywords:* injection, PLWH, unsafe injection, HIV, injection prevalence, injection practices
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Abstract

Objectives: In late 2014, an HIV outbreak occurred in rural Cambodia among villagers who received medical injections from unlicensed medical providers, justifying the need to assess medical injection practices among those who are at risk of acquiring and/or transmitting HIV.

This study examined medical injection/infusion behaviours among people living with HIV (PLWH) and those who were HIV-negative in Cambodia. These behaviours should be properly assessed, especially among PLWH, as their prevalence might influence a future risk of other outbreaks.

Design: A cross-sectional survey was conducted in order to examine injection behaviours and estimate injection prevalence and rates by HIV status. Unsafe injections/infusions were those received from village providers who do not work at a health centre or hospital, or traditional providers at participant's (self-injection included) or provider's home. Logistic regression was performed to examine the relationship between unsafe injection/infusion and HIV, adjusting for sex, age, education, occupation, residence location, and other risk factors.

Setting: The survey was conducted in 10 HIV testing and treatment hospitals/clinics across selected provinces in Cambodia, from February to March, 2017.

1
2
3
4 **Participants:** A total number of 500 volunteers participated in the survey, 250 PLWH and 250
5
6
7 HIV-negative individuals.

8
9
10 **Outcome measures:** Measures of injection prevalence and other risk behaviour were based on
11
12
13 self-reports.

14
15
16
17 **Results:** Both groups of participants reported similar past year's injection/infusion use, 47%
18
19
20 ($n=66$) among PLWH and 54% ($n=110$) HIV-negative participants ($P=.24$). However, 15%
21
22
23 ($n=11$) of PLWH reported having received unsafe last injection compared to only 7% ($n=11$) of
24
25
26 HIV-negative participants. In logistic regression, this association remained numerically positive,
27
28
29 but was not statistically significant (adjusted odds ratio 1.84 [95% CI: 0.71-4.80]).

30
31
32
33 **Conclusions:** The inclination for medical injections and infusions (unsafe at times) among
34
35
36 PLWH and the general population in Cambodia was common and could possibly represent yet
37
38
39 another opportunity for parenteral transmission outbreak.
40
41
42

43 44 45 46 47 **Strengths and limitations of this study**

- 48
49
50 • By accounting for the types of facilities at which injections and infusions were carried
51
52
53 out, as we have done in our study, we were able to ascertain that the outcome of the study

(the extent to which these injections/infusions could be interpreted as safe or unsafe) was measured reasonably accurately.

- One of the biggest issues in any cross-sectional studies is reverse causation; however, this was highly unlikely in our study.
- Medical injection and infusion practices were assessed through self-reports, which could lead to bias.
- In order to have a complete understanding of the injection and infusion practices, the prescription tendencies of care providers should have also been assessed, but our work was only able to assess these practices among PLWH and those who were HIV-negative across the 10 selected study sites.

Introduction

The World Health Organization (WHO) considered over or unnecessary use of injections as unsafe injection practices, alongside the use of unsafe methods for injection, such as reusing syringe and needles [1, 2]. In some parts of the world, particularly in low- and middle-income countries (LMICs), this common medical procedure is being performed daily using unsafe (yet

1
2
3
4 avoidable) injection practices which put both PLWH and communities at risk of bloodborne
5
6
7 pathogen transmission [1-5]. In late 2014, a rural community in Cambodia had a large outbreak
8
9
10 of human immunodeficiency virus (HIV) when an unlicensed medical practitioner infected 242
11
12
13 villagers aged between 2 and 89 years through his use of contaminated injection equipment [6,
14
15
16
17 7]. In early 2018, another two HIV outbreaks linked with unsafe injection practices occurred in
18
19
20 India and Pakistan [3]. In Iran, the behavioural survey among people who inject drugs (PWID)
21
22
23 demonstrated a positive correlation between risky and unsafe injection use and the prevalence of
24
25
26
27 HIV [8]. These incidents and reports demonstrated the ongoing risk of outbreaks related to
28
29
30 unsafe medical injection practices in many parts of the world. Additionally, a review article on
31
32
33 injection practices worldwide published in 2000 reckoned that many injections are unsafe and
34
35
36 unnecessary and that the region with the highest unsafe practice (reuse of injection materials)
37
38
39 was indeed in Southeast Asia [9].
40
41
42
43

44 In Cambodia, private health care providers are commonly sought for care. Although
45
46
47 many of them are public healthcare workers who practice privately during off-working hours,
48
49
50 there are also providers, mainly in rural areas, who are unlicensed private practitioners from
51
52
53 whom the community seeks medical care including (but not limited) to injections and infusions.
54
55
56
57
58
59
60

1
2
3
4 This is not uncommon in some parts of LMICs in which a person without proper training or
5
6
7 education in administering certain medical procedures provides medical injections [4].
8
9

10 The last Cambodia Demographic and Health Survey (Cambodia DHS 2014) assessed
11
12 injection practices as part of their behavioural survey among the general population. According
13
14 to their report, the prevalence of medical injection (having had any medical injections from
15
16 health worker in the past 12 months) among the Cambodian population aged 15-49 was
17
18 approximately 35% (or 37% and 27% among women and men, respectively) [10]. Previous
19
20 studies on injection use and safety practices (including the DHS survey) in Cambodia usually
21
22 focused on the general population [11]. Moreover, although according to the 2019 review on
23
24 injection practices using the DHS data from 40 countries reported reduced numbers of unsafe
25
26 injections in 81% of the countries, the data used was from 2011-2015 [12], no other assessment
27
28 had been reported since then. Until the present work, these behavioural risk factors have not been
29
30 studied among people living with HIV (PLWH), despite the fact that the risk of getting or
31
32 transmitting bloodborne pathogens among this population are heavily shaped by these
33
34 behaviours. We hypothesized that PLWH might be seeking or receiving more medical injections
35
36 (likely unnecessary and unsafe) than the general population for several reasons. First, being in
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 regular care gives PLWH more opportunities to get diagnosed with various medical conditions
4
5
6 and receive treatments. Second, PLWH often suffer from significantly more co-morbidities, such
7
8
9 as age-related non-communicable diseases and mental or neurological disorders, than the general
10
11
12 population [13, 14]. For these reasons, PLWH might be in greater need of medical treatments,
13
14
15 such as injections, than the general population.
16
17
18
19

20 Ever since the 2014 HIV outbreak in Roka village, there have been no other studies
21
22
23 assessing injection behaviours among PLWH elsewhere; and the Cambodia DHS reported only
24
25
26 medical injections given by health care workers. Without assessment of injection and infusion
27
28
29 practices in people who are at risk of transmitting and acquiring HIV, it is challenging for public
30
31
32 health professionals to advise or prepare public health measures which are both appropriate and
33
34
35 efficient to address unsafe injection practices. Our study aims to primarily characterize injection
36
37
38 practices among PLWH and those who were HIV-negative and determine whether the first group
39
40
41 were more likely to seek unsafe or unnecessary medical injections.
42
43
44
45
46

47 Although when considering unsafe medical injections, people usually refer to used
48
49
50 syringes and needles, we considered (in this paper) injections provided by unlicensed (medical)
51
52
53 practitioners unsafe as well. Understanding these injection seeking behaviours among this
54
55
56
57
58
59
60

1
2
3
4 population is helpful for planning necessary public health measures as well as improving access
5
6
7 to formal healthcare facilities.
8
9

10 **Methods**

11 12 13 **Study design and setting**

14
15
16
17 We conducted a cross-sectional study among PLWH ($n=250$) who came to receive their HIV
18
19
20 treatment care and those who came to have HIV testing and had a negative result ($n=250$) at 10
21
22
23 selected HIV clinics in five provinces and the capital city (Phnom Penh) of Cambodia, from
24
25
26
27 early February to the end of March 2017. The sample size of 250 per group was calculated to
28
29
30 provide 90% power to test the hypothesis using a two-sample comparison of proportions where
31
32
33 the first proportion was set at 20% of injection use (HIV-negative participants) and the second
34
35
36 proportion was set at 35% (HIV-positive participants). In Cambodia, HIV voluntary testing sites
37
38
39 in Cambodia and HIV/AIDS treatment and care clinics (called Opportunistic
40
41
42
43 Infections/Antiretroviral Therapy (OI/ART) sites) and are under the supervision of the National
44
45
46
47 Centre for HIV/AIDS, Dermatology and STD (NCHADS); there are around 52 of them across
48
49
50
51 Cambodia at the time of the study.
52
53
54
55
56
57
58
59
60

1
2
3
4 A two-stage sampling approach was employed for participant selection. We selected 10
5
6
7 sites and out of the 52 sites with joint testing/OI/ART services (meaning those with both testing
8
9
10 and OI/ART services) using probability-proportional-to-size (PPS) method. Then, from each of
11
12
13 these 10 sites, we consecutively sampled 25 PLWH who came for their regular clinic visit or
14
15
16 pharmacy refill. In a similar manner, HIV-negative individuals who came to each selected sites
17
18
19 for HIV testing who got a negative result were approached for recruitment (25 per site).
20
21
22

23 **Inclusion and exclusion criteria**

24
25
26 Both PLWH and HIV-negative participants were eligible if they were at least 18 years old and
27
28
29 were willing and able to provide written informed consent to take part in the study on the data
30
31
32 collection day. Excluded were individuals who were not willing or able to complete the
33
34
35 questionnaire, had undetermined test result, or presented any other condition that, in the opinion
36
37
38 of the research or local healthcare staff, would preclude informed consent.
39
40
41
42

43 **Medical history and behavioural assessment**

44
45
46 HIV-specific factors (e.g. HIV status, date of HIV test, WHO disease stage, etc.) were obtained
47
48
49 from linkage with the NCHADS database. Behavioural data were collected using a Computer-
50
51
52 Assisted Person Interview (CAPI) technique, administered via tablet and questions were guided
53
54
55
56
57
58
59
60

1
2
3
4 by the literature. Participants were asked to report on socio-demographic factors, such as date of
5
6
7 birth, sex, education, marital status, occupation, general location of residence (village,
8
9
10 community, district and province) and a wide range of behavioural factors including history of
11
12
13 illicit injection drug use (IDU), alcohol and tobacco use and informal medical injection/infusion
14
15
16 use (frequency, and type of provider).
17
18
19

20 **Definition and classification**

21
22
23
24 The outcome of interest, unsafe medical injection (binary outcome), was defined as having
25
26
27 received the last injection or infusion (within the past year) from village providers who do not
28
29
30 work at a health centre or hospital, from traditional providers, or by self-injection (other than
31
32
33 diabetic medication) either at their own home or at the provider's home. In Cambodia and
34
35
36 especially in rural areas, these health workers might also provide some basic medical services
37
38
39 (including injections and infusions) at their patient's home or in private hospitals/clinics.
40
41
42
43

44 Therefore, regardless of where the PLWH received the injections, as long as they were provided
45
46
47 by the providers who worked at a hospital or health centre, we considered these injections safe.
48
49

50 Both intravenous and intramuscular injections were included in the questionnaire and reporting.
51
52
53
54
55
56
57
58
59
60

1
2
3
4 The prevalence of medical injections included those who reported at least one injection or
5
6
7 infusion (over the past year), but excluded vaccinations, non-medical injections and rare medical
8
9
10 injections such as transfusion.
11

12
13 The HIV status was not assessed by the study team, those with known HIV-positive or
14
15
16 HIV-negative results were informed of the present study and referred by their care providers to
17
18
19 the study team for further information on the study and consent process. We had no access to
20
21
22 their HIV test or result.
23
24

25
26
27 Other risk behavioural assessment (alcohol and tobacco use, informal medical
28
29
30 injection/infusion use, etc.) was based on participants' self-report.
31

32 33 **Statistical analysis**

34
35
36 We computed percentages and means of the key characteristics by HIV status. We calculated the
37
38
39 prevalence of having had at least one medical injection from health workers and from all
40
41
42 provider types over the past year among the participants (by their HIV status). Chi-square and
43
44
45 Fishers' exact tests were performed for categorical variables and t-tests for continuous variables.
46
47
48
49
50 Next, the average number of past year's medical injections from each type of providers by HIV
51
52
53 status was also computed and we reported the *P* derived from Poisson regression. Finally, to
54
55
56
57
58
59
60

1
2
3
4 examine the relationship between unsafe medical injection practices and HIV status, we
5
6
7 performed logistic regression, adjusting for sex, age, education, occupation, residence location,
8
9
10 injection preference and other risk factors. Confounding variables were based on prior
11
12
13 knowledge and literature review on similar work previously conducted [12, 15, 16]. All analyses
14
15
16 were done in STATA 14.
17
18

19 20 **Patient and public involvement** 21

22
23 The PLWH, care givers and those who sought HIV testing but were negative participated in the
24
25
26 data collection of the study. Preliminary results of the study had been presented at the University
27
28
29 of Health Sciences at the 2018 Scientific Days among invited care givers, students and other
30
31
32 invited guests and researchers.
33
34
35

36 37 **Results** 38

39
40 We presented key characteristics by HIV status in Table 1. The socio-demographic factors are
41
42
43 vastly different between the two groups in terms of age, marital status, educational background
44
45
46 and occupation. PLWH appeared to be much older – mean age was 43 years (standard deviation
47
48
49 [SD] 9), of a lower educational background and married, while the majority of HIV-negative
50
51
52 participants were younger – mean age was 31 years (SD 11), more educated and single.
53
54
55
56
57
58
59
60

1
2
3
4 However, both groups were comparable in terms of their sex, income and residence location
5
6
7 distribution. Female participants accounted for about 66% ($n=164$) of PLWH and 71% ($n=177$)
8
9
10 of those uninfected. The majority of participants from both groups were from the provinces, 91%
11
12
13 ($n=227$) among PLWH and 93% ($n=231$) among the uninfected.
14
15
16

17 **Table 1. Key characteristics of study participants by HIV status, Informal Medical Injection**

18
19
20 **Study ($n=500$), Cambodia, 2017**
21
22

Socio-demographics	HIV+		HIV-		<i>P</i>
	<i>(n=250)</i>		<i>(n=250)</i>		
	<i>n</i>	<i>%</i>	<i>n</i>	<i>%</i>	
Gender					
Female	164	65.6	177	70.8	.21
Male	86	34.4	73	29.2	
Age ^a (Mean, SD)	(43.1, 9.0)		(30.6, 10.7)		<.001
Marital status					
Single	15	6.0	87	34.8	<.001
Married	140	56.0	141	56.4	
Divorced	41	16.4	15	6.0	
Widowed	54	21.6	7	2.8	
Education					
Secondary or higher	104	41.6	163	65.2	<.001
Primary or less	146	58.4	87	34.8	
Occupation ^a					
Unemployed	81	32.7	126	50.8	<.001
Self-employed/farmers	95	38.3	70	28.2	
Employed	72	29.0	52	21.0	
Household annual income ^{a,b} (USD)					
> 3,000	40	22.9	44	22.8	.48

1,800-3,000	45	25.7	42	21.8	
1,001-1,800	39	22.3	56	29.0	
≤ 1,000	51	29.1	51	26.4	
Current address ^a					
Province	227	90.8	231	92.8	.42
Phnom Penh (capital city)	23	9.2	18	7.2	
Other behavioural risk factors ^c					
Smoke monthly or more often	30	12.0	13	5.2	<.01
Feeling drunk at least once a month	45	18.0	63	25.2	.05
Contact with syringe and needle at workplace	8	3.2	36	15.5	<.01
Had at least one hospitalization	42	23.5	87	49.2	<.001

SD, standard deviation.

^aMissing (HIV+, HIV-, respectively): age ($n=5$, $n=5$); occupation ($n=2$, $n=2$); current address ($n=0$, $n=1$).

^bThe categories for household income used quartiles to assure sufficient numbers in each category.

^cSelf-report over the past year.

Injection/infusion use

Injection and infusion practices are described in Table 2. We found that the average annual number of injection/infusion from health workers was about three and four injections per person among PLWH and those who were HIV-negative, respectively ($P<.001$). The prevalence of any medical injection/infusion provided by health workers over the past year was higher among HIV-uninfected participants, 72% ($n=153$), compared to 40% ($n=61$) among those who were HIV-positive ($P<.001$). However, the prevalence of past year's injection/infusion from all providers

between the two groups were comparable, 47% ($n=66$) among PLWH and 54% ($n=110$) among those uninfected ($P=.24$).

Table 2. Injection and infusion seeking behaviours of study participants by HIV status, Informal Medical Injection Study ($n=500$), Cambodia, 2017

Injection and infusion practices	HIV+		HIV-		<i>P</i>
	<i>n</i> = 250		<i>n</i> = 250		
	<i>n</i>	%	<i>n</i>	%	
Injection and infusion received					
Last injection/infusion within past year					
Given by relative/acquainted provider	51	23.0	50	22.8	.97
Recommended by provider	54	85.7	131	90.3	.33
Given at public hospital	35	44.9	97	54.5	.16
Given at private hospital/clinic	29	53.7	58	46.0	.35
Given at their own home	16	31.4	24	21.2	.16
Number of injections/infusions within past year					
More than a year ago	107	67.7	144	66.4	.78
From health workers (mean, SD)	(3.2, 7.5)		(4.3, 7.1)		<.001
From all providers (mean, SD)	(3.5, 7.1)		(4.4, 7.8)		<.001
At least one - health worker	61	40.4	153	72.5	<.001
At least one - all providers	66	47.5	110	53.9	.24
Prefer injection to other treatments ^a	124	49.6	145	58.0	.06
Injection and infusion safety					
Last injection within past year					
Unsafe ^b last injection	11	15.5	11	7.3	.06
Provider did not use new, unopened syringe/needle	0	0.0	6	3.8	.19
Last injection within past year					
Unsafe ^b last infusion	10	13.5	13	10.5	.52

Provider did not use new, unopened syringe/needle	0	0.0	3	2.5	.55
---------------------------------------------------	---	-----	---	-----	-----

SD, standard deviation.

^aThe questions on this preference pertain to several tracer conditions (in which case medical injections are clearly unnecessary).

^bAdministered at participant's or provider's home by village providers who do not work at health centre or hospital, traditional providers, or self-injection.

When asked about the last injection/infusion they received within the past year, PLWH were more likely to report having received their last one(s) at a private hospital/clinic, 54 % ($n=29$), or at their own home, 31% ($n=16$), compared to a 46% ($n=58$) and 21% ($n=24$), respectively, reported by their HIV-negative counterparts. HIV-negative participants were more likely to have received their last injection/infusion at a public hospital, 54% ($n=97$), as opposed to 45% ($n=35$) of PLWH ($P=.16$). Figure 1 broke down last injection and infusion by facility types in more details. [insert Figure 1 here]

Regardless of HIV status, public and private sector accounted for the majority of medical injection and infusion received. Although none of our PLWH reported having received their last injection or infusion at traditional healer's home, about one-fourth of them reported having received their last injection (15% ($n=9$)) and infusion (22% ($n=14$)) at their own home.

1
2
3
4 A large number of participants from both groups, 50% ($n=124$) of PLWH and 58%
5
6
7 ($n=145$) of those uninfected, reported that they preferred injection/infusion to other forms of
8
9
10 treatment when sick ($P=.06$). Moreover, more than 60% of participants from both groups
11
12
13 indicated that they had actually received more injections the past year than previous year.
14
15
16 Similarly, over 80% of both PLWH and HIV-negative participants reported that their last
17
18
19 injection was in fact recommended by their care provider.
20
21
22

23 **Injection/infusion safety practices**

24
25
26 About 4% ($n=6$) of HIV-negative participants reported that the provider for their last injection
27
28
29 did not use a new, unopened package of syringe and needles while none of PLWH reported this
30
31
32 practice ($P=.06$). Although the average annual injection/infusion rates from all provider types
33
34
35 (including health workers) were slightly lower among PLWH (three injections per person)
36
37
38 compared with those who were HIV-negative (four injections per person) ($P<.001$), we observed
39
40
41 a slightly larger proportion of PLWH reported an unsafe last injection within the past year, 15%
42
43
44 ($n=11$) vs 7% ($n=11$) reported by those who were HIV-negative ($P=.06$). Likewise, 13% ($n=10$)
45
46
47
48
49 of PLWH reported an unsafe last infusion within the past year, compared to 10% ($n=13$) of HIV-
50
51
52
53 uninfected participants ($P=.52$). Regardless of whether they live in the provinces or the capital
54
55
56
57
58
59
60

1
2
3 city “Phnom Penh” (Figure 2), the majority of participants from both groups reported their
4
5
6
7 provider recommended their last injection/infusion and more HIV-negative participants than
8
9
10 PLWH received their last injection/infusion from health workers. [insert Figure 2 here] In figure
11
12
13 3, overall, we saw similar patterns across the country, except provinces in the central and north-
14
15
16 eastern parts of Cambodia where injection/infusion use appeared the highest. [insert Figure 3
17
18
19
20 here]
21
22

23 **Association between unsafe medical injection/infusion and HIV**

24
25
26
27 Table 3 presents the crude odds ratio (cOR), adjusted OR (aOR) and the 95% CIs of the
28
29
30 relationship between unsafe last medical injection and HIV status. Before adjustment, only sex,
31
32
33 occupation and presence of two or more risk behaviours were associated with having had unsafe
34
35
36 last injection or infusion (Table 3). The association between unsafe medical injection/infusion
37
38
39 and HIV status was numerically positive but was not statistically significant (cOR=1.45 [95%
40
41
42 CI: 0.70-3.00]). After adjusting for other covariates, the aOR was 1.84 (95% CI: 0.71-4.80),
43
44
45
46
47 remaining statistically non-significant.
48
49

50
51 **Table 3. Association between getting unsafe medical injection and HIV status, Informal Medical**
52
53
54 **Injection Study ($n=500$), Cambodia, 2017**
55
56
57
58
59
60

Outcome: unsafe injection/infusion	Crude OR	95 % CI	Adjusted OR^a	95 % CI
HIV + (ref. HIV-)	1.45	0.70-3.00	1.84	0.71-4.80
Male (ref. female)	2.17	1.03-4.57	2.37	1.00-5.62
Age	1.00	0.97-1.03	0.98	0.94-1.02
Education (ref. secondary or higher)				
Primary or less	0.70	0.33-1.46	0.96	0.41-2.23
Occupation (ref. unemployed)				
Farmers and self-employed	0.91	0.41-2.01	0.83	0.36-1.91
Employed	0.48	0.17-1.36	0.59	0.20-1.72
Current address in Phnom Penh (ref. in provinces)	1.18	0.33-4.23	1.02	0.27-3.88
Prefer injection or infusion when sick (ref. no preference)	0.59	0.29-1.21	0.66	0.32-1.40
Had at least two risk behaviours ^b	0.67	0.19-2.33	0.47	0.13-1.75

OR, odds ratio. CI, confidence

interval.

Unsafe injection/infusion: last injection/infusion within the past year administered at participant's or provider's home by village providers who do not work at health centre or hospital, traditional providers, or self-injection.

^aAdjusted for gender, age, education, occupation, residence location, injection or infusion preference, and presence of two or more risk behaviours.

^bCombination of risk behaviours include: one or more hospitalization, contact with syringe and needle, smoking monthly or more often and feeling drunk monthly or more often in the past year.

Discussion

In our study, we found a high prevalence of medical injections (having had any medical injections in the past year from health workers) among the study participants in general (almost 60%), but PLWH were more likely to have had unsafe last injection or infusion (having received

1
2
3
4 their last injection from informal providers), compared with those who were HIV-negative.
5

6
7 Regardless of the reasons for medical injections (with few exceptions), this practice is very
8
9
10 common, and should be addressed, whether it is the PLWH's false beliefs that injectable drugs
11
12
13 work better than oral ones for certain medical conditions or the tendency to over-prescribe these
14
15
16 injectables.
17
18

19
20 According to the 2014 CDHS, there were great variations of injection prevalence
21
22
23 (administered by health workers) ranging from 12% to 45% and the average annual number of
24
25
26 injections is one to two per person [10]. We found a much higher prevalence among our study
27
28
29 sample, our results were more in line with an article published in 2004 by Vong et al. that also
30
31
32 looked at medical injections in Cambodia found 40% of medical injection prevalence and
33
34
35 average number of injection (over the past six months) of 5.9 per person [11]. This is, in fact,
36
37
38 consistent with findings from a review paper published in 2016 which found that the 12-month
39
40
41 medical injection prevalence ranged from 30% to 68% across studies conducted in South Asia
42
43
44 [17]. It should be noted that both the 2004 study and the 2014 DHS examined the injection
45
46
47 practices among the general population outside of HIV setting (treatment or testing), and that it
48
49
50 was unclear in the CDHS if infusions were also counted for their injection reporting. Our study
51
52
53
54
55
56
57
58
59
60

1
2
3
4 grouped infusions with injections when reporting prevalence, similar to the 2004 study (Vong et
5
6
7 al), but our study reported the injection behaviours over the past year instead of over six months
8
9
10 like Vong et al did. Several other factors such as limited education, tendency of prescribers to
11
12
13 recommend and participant's personal preference of injection and the study population could be
14
15
16 responsible for higher rates being reported in our study compared with others. However, these
17
18
19 seemed consistent with a recently published paper which found high Hepatitis C prevalence
20
21
22 among Cambodian population that is likely due to medical injections [16]. High prevalence of
23
24
25 medical injection (ranging from 30% to 68%) had also been reported across studies conducted in
26
27
28 south Asia [17]. Results from Kenyan survey published in 2016 suggested a positive association
29
30
31 between HIV and those who reported having received injection in the last 12 months [18].
32
33
34 Although it should be noted that the Kenyan study only reported injections from care providers
35
36
37 and not traditional healers or other types of providers.
38
39
40
41
42
43

44 The older mean age of our PLWH might also explain the high prevalence of medical
45
46
47 injections among them. Because PLWH in the study were on average older, they could be sicker
48
49
50 and, therefore, sought more medical procedures including injections. The age distribution of
51
52
53
54
55
56
57
58
59
60

1
2
3 PLWH in Cambodia is actually weighed down by those who had been infected in the early 90's;
4
5
6
7 and fewer people had become infected since 2000 [19].
8
9

10 The study should be interpreted with consideration to a number of limitations. Our
11
12 assessment of the outcome was based on self-recall which could result in misclassification of the
13
14 outcome measured. However, we have limited recalls to the past 12 months and reckon that to
15
16 avoid capturing only certain fluctuations, a recall over 12 months appeared reasonable. Multiple
17
18 studies used a 12-month timeframe for estimating prevalence (although they mainly assessed
19
20 drug use) [20, 21]. Medical injections are generally also uncommon events, we, therefore,
21
22 expected this misclassification, if any, to be minimal. By design, the outcome-exposure
23
24 relationship in our study is obscure. However, our PLWH were mostly prevalent cases and older
25
26 – 92% of PLWH had been diagnosed more than two years prior (result not shown) – who were
27
28 most likely got infected during the early 90's through unsafe sexual behaviours and not through
29
30 unsafe injection practices. Consecutive sampling among PLWH and HIV-negative participants
31
32 could also affect our internal validity; however, the process of scheduling the appointment at
33
34 each selected facility for both groups is already in itself a random process. There were also
35
36 patients who just dropped in. In other words, there is no reason to believe that participants might
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 differ in terms of injection use between the time of our data collection and any other time. This
4
5
6
7 does, however, limit our own study findings' generalizability in a way that they might be
8
9
10 applicable to only PLWH and HIV-negative population who come to receive care and seek HIV
11
12
13 testing at the selected clinics and hospitals.
14
15

16
17 The strengths of our study included the fact that we accounted for not only both the
18
19
20 provider of the last injection or infusion received within the past year, but also the facility at
21
22
23 which these medical procedures were given. The combination of both provider and facility types
24
25
26 should be able to capture better the safety aspect of medical injection/infusion. It should be noted
27
28
29 that private facilities in Cambodia are generally considered "formal" providers. Our work is one
30
31
32 of the few studies which examined injection practices among PLWH over the past decade.
33
34

35
36
37 Another study was conducted in 2016 (a year prior to when our study had started) [16].
38
39

40
41 Regardless, additional studies are necessary in order to confirm the findings from our work and
42
43
44 understand the true underlying injection practices among PLWH.
45
46

47 **Implications on policy and practices**

48
49

50
51 Better access to medical care is a challenge particularly in rural parts of Cambodia. Our findings
52
53
54 suggest the need to pull resources toward universal health coverage and educational programs on
55
56
57

1
2
3 safe medical injection practices. Resources are always limited in LMICs; therefore, support
4
5
6
7 development partners play important roles in addressing these health needs. Besides these, other
8
9
10 important educational programs or activities directed at both PLWH and HIV-negative
11
12
13 population are also deemed beneficial. Care providers could be important role models in
14
15
16 enforcing correct practices of medical injection, particularly counsellors in the setting of
17
18
19 HIV/AIDS care here could also play that role. Several HIV health facilities offered a digital
20
21
22 platform of communication (Telegram group chat and Facebook Messenger chats are the most
23
24
25 commonly used), on a voluntary basis, to PLWH and care providers to interact with one another
26
27
28 on their HIV-related issues. These platforms could also be used as forums for communicating
29
30
31 correct safe injection practices to them. Of course, these types of programs would need further
32
33
34 investigations in order to understand the population whom we could reach with these digital
35
36
37 platforms. Regardless of HIV status, these educational programs and activities should be widely
38
39
40 inclusive because use of medical injection seemed to be very common among both PLWH and
41
42
43 those who were HIV-negative. Nevertheless, further investigations on the injection practices
44
45
46 (among care provider) and the benefits of the aforementioned educational platforms would
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 provide a more complete picture of the practices of medical injections in Cambodia and evidence
4
5
6
7 as to whether they are beneficial or if additional programs are to be put in place.
8
9

10 **Conclusions**

11
12
13 The majority of the Cambodian population, including those who are living with HIV, regard
14
15
16 medical injections and infusions as a symbol for optimal medical care. Although on average, they
17
18
19 might have received slightly fewer number of annual injections, PLWH were as likely to have
20
21
22 received unsafe last injection/infusion within the past year as those who were HIV-negative. This
23
24
25
26
27 practice poses harms to themselves as well as their community and needs to be addressed among
28
29
30 all stakeholders including providers who are able to prescribe medical injections including
31
32
33 infusions. Our findings suggested the need to evaluate and reinforce safe injection practices among
34
35
36
37 health workers for a complete assessment and understanding of medical injection education and
38
39
40 practices in the health system.
41
42
43
44
45

46 **Contributors**

47
48
49 KS conducted literature search and data analysis, interpreted results, wrote the manuscript, and
50
51
52 created figures. KK and KV conducted literature search, designed the study, collected the data
53
54
55 and guided data interpretation. D.K. conducted literature search and collected the data. VS and
56
57
58
59
60

1
2
3
4 PG conceptualized the study, conducted literature search, interpreted results and guided data
5
6 interpretation. All authors provided critical feedback and shaped the final manuscript.
7

8 **Funding**

9
10 This work was supported by the UCLA Centre for AIDS Research/AIDS Institute grant # 5P30
11
12
13 AI28697.
14
15

16 **Competing interests**

17
18 None declared.
19
20

21 **Patient consent for publication**

22
23 Not applicable.
24
25

26 **Data availability statement**

27
28 The data used to support the findings of this study are available from the corresponding author
29
30 upon request.
31
32

33 **Ethics approval**

34
35
36
37 Written consent was obtained from each participant before the enrolment and interview process.
38
39

40 All interviews were conducted in a private room at the health centres/clinics. All instruments used
41
42

43 for data collection were anonymous; no identifying information, such as name, address, telephone
44
45

46 number, or date of birth was recorded. The HIV-related information, such as ART regimen and
47
48

49 duration of HIV infection, were obtained from linking the patient's ART code to the national HIV
50
51

52 database. The ART code for each patient is given by the HIV clinics once the PLWH are linked to
53
54
55
56
57
58
59
60

1
2
3 care and is used as their identifier instead of their name in the national database. After the dataset
4
5
6
7 had been linked, the ART code had been removed for all participants. The study data was stored
8
9
10 on a personal computer, keyword-protected. The study protocol was approved by the University
11
12
13 of California Los Angeles Institutional Review Board (UCLA-IRB# 16-000876) and the National
14
15
16
17 Ethics Committee for Human Research (NECHR) of Cambodia (NECHR# 320) in 2016.
18
19

20 **References**

- 21
22
23
24 1. World Health Organization. WHO guideline on the use of safety-engineered syringes for
25
26 intramuscular, intradermal and subcutaneous injections in health care settings. Geneva: World
27
28 Health Organization, 2016.
29
30
- 31
32 2. World Health Organization. Injection Safety: Questions and Answers. 2016.
33
34 https://www.who.int/infection-prevention/publications/is_questions-answers.pdf?ua=1 (July
35
36 2020, date last accessed).
37
38
- 39
40 3. Altaf A. Unsafe Injection Practices by Medical Practitioners in South Asia Associated with
41
42 Hepatitis and HIV Outbreaks. *J Infectiology* 2018;1(2):1-3.
43
44
- 45
46 4. Gupta E, Bajpai M, Sharma P, Shah A, Sarin S. Unsafe injection practices: a potential
47
48 weapon for the outbreak of blood borne viruses in the community. *Ann Med Health Sci Res.*
49
50 2013;3(2):177-81. Epub 2013/08/07. doi: 10.4103/2141-9248.113657. PubMed PMID: 23919185;
51
52 PubMed Central PMCID: PMCPMC3728858.
53
54
55
56
57
58
59
60

- 1
2
3
4 5. World Health Organization. Make Smart Injection Choices: National Decision-Making for
5 Safe and Appropriate Injections. 2017. [https://www.who.int/infection-](https://www.who.int/infection-prevention/tools/injections/IS_medical-treatment_leaflet.pdf?ua=1)
6 prevention/tools/injections/IS_medical-treatment_leaflet.pdf?ua=1 (July 2020, date last
7 accessed).
8
9
10
- 11
12
13 6. Rouet F, Nouhin J, Zheng DP, Roche B, Black A, Prak S, et al. Massive Iatrogenic
14 Outbreak of Human Immunodeficiency Virus Type 1 in Rural Cambodia, 2014-2015. *Clin Infect*
15 *Dis.* 2018;66(11):1733-41. Epub 2017/12/07. doi: 10.1093/cid/cix1071. PubMed PMID:
16 29211835; PubMed Central PMCID: PMC5963970.
17
18
19
- 20
21
22
23 7. Saphonn V, Fujita M, Samreth S, Chan S, Rouet F, Khol V, et al. Cluster of HIV Infections
24 Associated With Unsafe Injection Practices in a Rural Village in Cambodia. *J Acquir Immune*
25 *Defic Syndr.* 2017;75(3):e82-e6. Epub 2017/01/28. doi: 10.1097/QAI.0000000000001295.
26 PubMed PMID: 28129255; PubMed Central PMCID: PMC6814627.
27
28
29
- 30
31
32
33 8. Esmaeili A, Shokoohi M, Danesh A, Sharifi H, Karamouzian M, Haghdoost A, et al. Dual
34 Unsafe Injection and Sexual Behaviors for HIV Infection Among People Who Inject Drugs in Iran.
35 *AIDS and behavior.* 2019;23(6):1594-603. Epub 2018/11/22. doi: 10.1007/s10461-018-2345-5.
36 PubMed PMID: 30460664; PubMed Central PMCID: PMC6527484.
37
38
39
- 40
41
42
43 9. Hutin YJFH, Anja M; Armstrong, Gregory L. Use of injections in healthcare settings
44 worldwide, 2000: literature review and regional estimates. *Bmj.* 2003. doi:
45 10.1136/bmj.327.7423.1075.
46
47
48
- 49
50
51
52 10. National Institute of Statistics; Directorate General for Health; and ICF International.
53 Cambodia Demographic and Health Survey 2014. Phnom Penh, Cambodia, and Rockville,
54 Maryland, USA: National Institute of Statistics; Directorate General for Health; and ICF
55 International; 2015.
56
57

- 1
2
3
4
5
6 11. Vong S, Perz JF, Sok S, Som S, Goldstein S, Hutin Y, et al. Rapid assessment of injection
7 practices in Cambodia, 2002. *BMC public health*. 2005;5:56. Epub 2005/06/03. doi:
8 10.1186/1471-2458-5-56. PubMed PMID: 15929800; PubMed Central PMCID:
9 PMCPMC1173117.
10
11
12
13
14
15 12. Hayashi T, Hutin YJ, Bulterys M, Altaf A, Allegranzi B. Injection practices in 2011-2015:
16 a review using data from the demographic and health surveys (DHS). *BMC Health Serv Res*.
17 2019;19(1):600. Epub 2019/08/29. doi: 10.1186/s12913-019-4366-9. PubMed PMID: 31455315;
18 PubMed Central PMCID: PMCPMC6712605.
19
20
21
22
23
24
25 13. amFAR. HIV and Comorbidities: The Foundation for AIDS Research (amFAR); 2020.
26 <https://www.amfar.org/hiv-and-comorbidities/> (July 2020, date last accessed).
27
28
29
30
31 14. World Health Organization. Chronic comorbidities and coinfections in PLHIV.
32 <https://www.who.int/hiv/topics/comorbidities/about/en/> (July 2020, date last accessed).
33
34
35
36 15. Janjua NZ, Akhtar S, Hutin YJ. Injection use in two districts of Pakistan: implications for
37 disease prevention. *Int J Qual Health Care*. 2005;17(5):401-8. Epub 2005/05/11. doi:
38 10.1093/intqhc/mzi048. PubMed PMID: 15883127.
39
40
41
42
43
44 16. Pheng P, Meyer L, Segeal O, Chea P, Yi S, Tuot S, et al. Hepatitis C seroprevalence
45 among people living with HIV/AIDS and pregnant women in four provinces in Cambodia: an
46 integrated bio-behavioral survey. *BMC Infect Dis*. 2022;22(1):177. Epub 2022/02/24. doi:
47 10.1186/s12879-022-07163-2. PubMed PMID: 35193496; PubMed Central PMCID:
48 PMCPMC8862396.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 17. Janjua NZ, Butt ZA, Mahmood B, Altaf A. Towards safe injection practices for prevention
5 of hepatitis C transmission in South Asia: Challenges and progress. *World J Gastroenterol.*
6 2016;22(25):5837-52. Epub 2016/07/20. doi: 10.3748/wjg.v22.i25.5837. PubMed PMID:
7 27433097; PubMed Central PMCID: PMC4932219.
8
9
10
11
12
13 18. Kimani D, Kamau R, Ssempijja V, Robinson K, Oluoch T, Njeru M, et al. Medical
14 injection use among adults and adolescents aged 15 to 64 years in Kenya: results from a national
15 survey. *J Acquir Immune Defic Syndr.* 2014;66 Suppl 1:S57-65. Epub 2014/01/15. doi:
16 10.1097/QAI.000000000000106. PubMed PMID: 24413041; PubMed Central PMCID:
17 PMCPMC4794988.
18
19
20
21
22
23
24
25 19. Ministry of Health/National Center for HIV/AIDS, Dermatology and STDs
26 (MOH/NCHADS). Annual Report 2016. National Center for HIV/AIDS, Dermatology and STDs.
27 2017.
28
29
30
31
32
33 20. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global
34 prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV,
35 HBV, and HCV in people who inject drugs: a multistage systematic review. *Lancet Glob Health.*
36 2017;5(12):e1192-e207. Epub 2017/10/28. doi: 10.1016/S2214-109X(17)30375-3. PubMed
37 PMID: 29074409; PubMed Central PMCID: PMC5683738.
38
39
40
41
42
43
44 21. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Methodological
45 Guidelines to Estimate the Prevalence of Problem Drug Use on the Local Level. Lisbon:
46 EMCDDA, December 1999.
47
48
49
50
51

52 **Figure titles and legends**


53
54
55
56
57
58
59
60

1
2
3
4 **Figure 1. Injection and infusion use among study participants by types of facility**
5
6

7 **Figure 2. Injection and infusion use among study participants by residence location – Phnom Penh**
8 **vs provinces**
9



10
11
12 **Figure 3. Injection and infusion use among study participants by geographic distribution**

13 Note: West: Pursat; North-west: Siem Reap, Battambang, Odor Meanchey, Banteay Meanchey;
14 South: Takeo, Kampot, Prey Veng; South-central: Phnom Penh, Kampong Speu; South-west:
15 Sihanoukville, Koh Kong; East: Kratie, Mondulkiri; South-east: Tbong Khmum, Svay Rieng,
16 Kampong Cham, Kandal; Central: Kampong Thom, Kampong Chhnang; North-east: Steung
17 Treng; North: Preah Vihear
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




% of participants having had last injection/infusion (past 12 month)
 For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Source: data from the 2017 Medical Injection Study (N=500), Cambodia



For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Section in manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Abstract/Methods
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Background
Objectives	3	State specific objectives, including any prespecified hypotheses	Background/Paragraph 5
Methods			
Study design	4	Present key elements of study design early in the paper	Methods/Study design and setting subheading/Page 6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Methods/Study design and setting subheading/Page 6
Participants	6	(a) <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	Methods/ Study design and setting and Inclusion and exclusion criteria/Page 6-7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Methods/Definition and classification subheading/Page 7-8
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Methods/Medical history and behavioural assessment/page 7
Bias	9	Describe any efforts to address potential sources of bias	Discussion/Page 15-16
Study size	10	Explain how the study size was arrived at	Methods/Study design and setting subheading/Page 6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Results/Page 9-10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Method/Statistical analysis subheading/Page 8
		(b) Describe any methods used to examine subgroups and interactions	N/A
		(c) Explain how missing data were addressed	Missingness occurred in less than 10% across the majority of

variables (except
income).

(d) *Cross-sectional study*—If applicable, describe analytical methods taking account of sampling strategy N/A

(e) Describe any sensitivity analyses N/A

Continued on next page

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Methods/Study design, sampling and recruitment subheading/Page 5
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Result/Page 7-8
		(b) Indicate number of participants with missing data for each variable of interest	Result/Page 8
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	Result/Page 9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Results/Page 13
		(b) Report category boundaries when continuous variables were categorized	Result/Page 8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	Discussion/ Paragraph 2
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Discussion/Page 16-17
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Discussion
Generalisability	21	Discuss the generalisability (external validity) of the study results	Discussion/Paragraph 5
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Funding/Page 19

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at

1
2 <http://www.annals.org/>, and *Epidemiology* at <http://www.epidem.com/>). Information on the STROBE Initiative is
3 available at www.strobe-statement.org.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only